fluconazole has been researched along with l 743,872 in 253 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (1.58) | 18.2507 |
| 2000's | 90 (35.57) | 29.6817 |
| 2010's | 130 (51.38) | 24.3611 |
| 2020's | 29 (11.46) | 2.80 |
| Authors | Studies |
|---|---|
| Casadevall, A; Franzot, SP | 1 |
| Galgiani, JN; Krishnarao, TV | 1 |
| Jones, RN; Marco, F; Messer, SA; Pfaller, MA | 1 |
| Coleman, DC; Gee, S; Joly, S; Messer, SA; Pfaller, MA; Pujol, C; Soll, DR; Sullivan, DJ | 1 |
| Cardenas, ME; Cruz, MC; Del Poeta, M; Heitman, J; Perfect, JR | 1 |
| Ernst, EJ; Klepser, ME; Pfaller, MA | 1 |
| Bachmann, SP; López-Ribot, JL; Patterson, TF | 1 |
| Ernst, EJ; Klepser, ME; Lewis, RE; Pfaller, MA; Roling, EE; Wasson, A | 1 |
| Goodman, D; Jakubowski, A; Morris, C; Pamer, E; Sepkowitz, K | 1 |
| Arathoon, EG; DiNubile, MJ; Gotuzzo, E; Kartsonis, NA; Lupinacci, RJ; Noriega, LM; Sable, CA; Smietana, JM; Villanueva, A | 1 |
| Bachmann, SP; López-Ribot, JL; Ramage, G; VandeWalle, K; Wickes, BL | 1 |
| Bartizal, K; DiNubile, MJ; Hicks, PS; Kartsonis, N; Ryan, D; Sable, CA | 1 |
| Cuenca-Estrella, M; Mellado, E; Rodríguez-Tudela, JL | 1 |
| Diekema, DJ; Hollis, RJ; Jones, RN; Messer, SA; Pfaller, MA | 1 |
| Brown, AL; Greig, JR | 1 |
| Yamaguchi, H | 1 |
| McGee, WT; Tereso, GJ | 1 |
| Bocanegra, R; Graybill, JR; Hernandez, S; Larsen, RA; Najvar, LK | 1 |
| Grooters, AM; Taboada, J | 1 |
| Bachmann, SP; López-Ribot, JL; Patterson, TF; Ramage, G; VandeWalle, K; Wickes, BL | 1 |
| Bliss, JM; Gigliotti, F; Wellington, M | 1 |
| Boyken, L; Diekema, DJ; Hollis, RJ; Messer, SA; Pfaller, MA; Rice, C; Tendolkar, S | 1 |
| Daniault, G; Imbert, C; Imbert-Bouyer, S; Rodier, MH; Soustre, J | 1 |
| Höhl, R | 1 |
| Andrade, R; Bille, J; Cantón, E; Cuenca-Estrella, M; Davidson, A; Durussel, C; Ellis, D; Foraker, E; Fothergill, AW; Ghannoum, MA; Giacobbe, RA; Gobernado, M; Handke, R; Laverdière, M; Lee-Yang, W; Merz, WG; Motyl, M; Odds, FC; Ostrosky-Zeichner, L; Pemán, J; Perea, S; Perfect, JR; Pfaller, MA; Proia, L; Rex, JH; Rinaldi, MG; Rodriguez-Tudela, JL; Schell, WA; Shields, C; Sutton, DA; Verweij, PE; Warnock, DW | 1 |
| Arzeni, D; Baldassarri, I; Barchiesi, F; Giannini, D; Marigliano, A; Scalise, G; Spreghini, E | 1 |
| Kuijper, EJ; Kullberg, BJ; van 't Wout, JW; Verweij, PE | 1 |
| Orenstein, R; Prabhu, RM | 1 |
| D'Antonio, D; Di Bonaventura, G; Picciani, C; Piccolomini, R; Spedicato, I | 1 |
| MacCallum, DM; Odds, FC | 1 |
| del Castillo, M; Klein, F; Manganello, S; Orellana, N; Wainsztein, N | 1 |
| Burnie, JP; Matthews, RC; Nooney, L | 1 |
| Marr, K | 1 |
| Perfect, JR | 1 |
| De Alarcón, A; Hernández, A; Nevado, J | 1 |
| Arikan, S; Hascelik, G; Sancak, B | 1 |
| Steinbach, WJ | 1 |
| Kofla, G; Ruhnke, M | 1 |
| Kappe, R; Rimek, D; Singh, J | 1 |
| Cocuaud, C; Daniault, G; Imbert, C; Rodier, MH | 1 |
| Kardos, G; Majoros, L; Sipiczki, M; Szabó, B | 1 |
| Coco, BJ; Fothergill, AW; Kirkpatrick, WR; Oliveira, ER; Patterson, TF; Redding, SW | 1 |
| Cowen, LE; Lindquist, S | 1 |
| Barberi, W; Foà, R; Girmenia, C; Iori, AP; Martino, P; Micozzi, A; Moleti, ML | 1 |
| Amsden, JR; Gubbins, PO | 1 |
| Bedard, M; Lulic-Botica, M; Natarajan, G; Pappas, A; Rongkavilit, C | 1 |
| Colombo, GL; Morlotti, L; Serra, G | 1 |
| Aparicio, M; García Ramón, R; Miguel, A; Molina, P; Puchades, MJ | 1 |
| Athan, E; Hughes, A; Lye, DC; O'Brien, D | 1 |
| Cheeks, C; Fidel, PL; Leigh, JE; Lilly, EA; Shetty, KV | 1 |
| Golan, Y; Hadley, S; Pauker, SG; Wolf, MP; Wong, JB | 1 |
| Arend, SM; de Fijter, JW; de Vaal, BJ; Kuijper, EJ; van't Wout, JW | 1 |
| Beretz, L; Entz-Werlé, N; Herbrecht, R; Kara, F; Koffel, JC; Letscher-Bru, V; Levêque, D; Lioure, B; Lutun, P; Nivoix, Y; Remy, V; Rigolot, JC; Waller, J; Zamfir, A | 1 |
| Marik, PE | 1 |
| Cheong, HJ; Kim, JH; Kim, MJ; Kim, WJ; Park, DW; Shin, C; Sohn, JW | 1 |
| Buitrago, MJ; Cuenca-Estrella, M; Gomez-Lopez, A; Mellado, E; Monzon, A; Rodriguez-Tudela, JL | 1 |
| Casadevall, A; Martinez, LR | 1 |
| Ince, N; Kandirali, E; Karabay, O; Kocoglu, E; Madariaga, MG | 1 |
| Cappello, D; Di Mare, M; Fiamingo, P; Gagliano, M; Giuffrida, G; Macarone, M; Severino, V; Sorbello, M; Spataro, M; Veroux, M; Veroux, P; Vizcarra, D | 1 |
| Hsueh, PR; Huang, LM; Lin, KH; Shao, PL; Yang, SC | 1 |
| Assal, M; Bernard, L; Hoffmeyer, P; Legout, L; Lew, D; Rohner, P | 1 |
| Aquino, VR; Goldani, LZ; Lunardi, LW; Zimerman, RA | 1 |
| Manfredi, R; Sabbatani, S | 1 |
| Chang, SC; Diekema, DJ; Erzsebet, P; Gibbs, DL; Kibbler, C; Mendez, M; Newell, VA; Pfaller, MA | 1 |
| Jayasinghe, M; Röcken, M; Schaller, M; Schmidt, S; Walker, B | 1 |
| Corona, D; Gagliano, M; Giuffida, G; Macarone, M; Veroux, M; Veroux, P | 1 |
| Canton, E; Espinel-Ingroff, A; Gibbs, D; Wang, A | 1 |
| Pendrak, ML; Roberts, DD; Rodrigues, RG | 1 |
| Almyroudis, NG; Fothergill, AW; Kusne, S; Rinaldi, MG; Sutton, DA | 1 |
| Aoun, N; Baixench, MT; Bretagne, S; Dannaoui, E; Desnos-Ollivier, M; Garcia-Hermoso, D; Piketty, C; Ramires, S | 1 |
| Maida, CM; Milici, ME; Oliveri, S | 1 |
| Beltrame, A; Cerana, M; De Maria, A; Di Biagio, A; Pacini, D | 1 |
| Arslan, H; Azap, O; Can, F; Demirbileki, M; Timurkaynak, F | 1 |
| Kaplan, AA; Zar, R; Zar, T | 1 |
| Carrillo-Muñoz, AJ; Casals, JB; del Valle, O; Estivill, MD; Ezkurra, PA; Giusiano, G; Quindós, G; Santos, P | 1 |
| Forrest, GN; Johnson, JK; Weekes, E | 1 |
| Couet, W; Grégoire, N; Marliat, M; Venisse, N | 1 |
| Harkness, J; Marriott, D; Stark, D; van Hal, SJ | 1 |
| Ghannoum, M; Kabbara, N; Lacroix, C; Peffault de Latour, R; Ribaud, P; Socié, G | 1 |
| Chu, CC; Hsueh, PR; Ruan, SY | 1 |
| Clemons, KV; Martinez, M; Stevens, DA; Tong, AJ; van Asbeck, E | 1 |
| Ayala, J; Elizondo, M; González, GM | 1 |
| Gafter-Gvili, A; Goldberg, E; Leibovici, L; Paul, M; Vidal, L | 1 |
| Dinubile, MJ | 1 |
| Agarwala, SD; Fink, GR; Kombe, D; Wheeler, RT | 1 |
| Tu, EY | 1 |
| Basso, M; Costa, SF; Girão, E; Gobara, S; Gomes, LB; Levin, AS; Medeiros, EA | 1 |
| Bouza, E; Guembe, M; Guinea, J; Martín-Rabadán, P; Muñoz, P; Pérez-Parra, A | 1 |
| Chia, HY; Koh, LP; Liu, TC; Poon, LM; Tan, LK | 1 |
| Bernardo, SM; Lee, SA; Miceli, MH | 1 |
| Brilhante, RS; Cordeiro, Rde A; de Camargo, ZP; de Lima, RA; Medrano, DJ; Monteiro, AJ; Rocha, MF; Sidrim, JJ; Tavares, JL | 1 |
| Acar, P; Dulac, Y; Kreitmann, B; Mansir, T; Paranon, S; Talvard, M | 1 |
| Arellano, B; Baños, I; Corbacho, C; Cuervas-Mons, V; Duran, P; Jiménez, M; Marcos, R; Noblejas, A; Ramos, A; Sánchez-Romero, I; Sánchez-Turrión, V | 1 |
| Bonnal, C; Bouges-Michel, C; Bretagne, S; Chochillon, C; Dannaoui, E; Datry, A; Develoux, M; Dromer, F; Matheron, J; Paugam, A | 1 |
| Boikov, D; Nagappan, V; Vazquez, JA | 1 |
| Binning, MJ; Lee, J; Riva-Cambrin, JK; Thorell, EA | 1 |
| Erasmus, J; Mattiuzzi, GN; Sever, M; Verstovsek, S | 1 |
| Badali, H; De Hoog, GS; Illnait-Zaragozi, MT; Meis, JF; Najafzadeh, MJ | 1 |
| Della-Latta, P; Eschenauer, GA; Kludze-Forson, M; Kubin, CJ; Lam, SW | 1 |
| Dag, I; Kasifoglu, N; Kiraz, N; Kiremitci, A; Oz, Y; Yamac, M | 1 |
| d'Enfert, C; Rossignol, T; Vediyappan, G | 1 |
| Müller, FM; Salvenmoser, S; Seidler, M | 1 |
| Chandrasekar, PH; Cutright, JL; Krishnan-Natesan, S; Manavathu, EK | 1 |
| Arnold, TM; Dotson, E; Hage, CA; Sarosi, GA | 1 |
| Belda, S; Cremades, R; Lopez, P; Rodriguez, JC; Royo, G; Ruiz-Garcia, M; Soler, L | 1 |
| Arzeni, D; Barchiesi, F; Campanati, A; Cirioni, O; Gabrielli, E; Ganzetti, G; Giacometti, A; Kamysz, E; Kamysz, W; Offidani, A; Silvestri, C; Simonetti, O | 1 |
| Bretagne, S; Desnos-Ollivier, M; Dromer, F; Fontanet, A; Lortholary, O; Sitbon, K | 1 |
| Ko, KS; Lee, JY; Peck, KR; Song, JH | 1 |
| Azoulay, E; Echeverria, PM; Kett, DH; Vincent, JL | 1 |
| Abbes, S; Ayadi, A; Ben Jemaa, M; Bouaziz, M; Cheikhrouhou, F; Chelly, H; Hammami, B; Khaled, S; Makni, F; Néji, S; Sellami, A; Sellami, H | 1 |
| Kim, S; Ko, KS; Lee, MS; Lee, MY; Moon, SY; Son, JS | 1 |
| Andes, D; Arendrup, MC; Brown, SD; Diekema, DJ; Lockhart, SR; Motyl, M; Perlin, DS; Pfaller, MA | 1 |
| Cantón, E; Espinel-Ingroff, A | 1 |
| Darabi, T; Erdmann, E; Hoppe, UC; Joost, I; Motloch, LJ; Rottlaender, D | 1 |
| Lopez-Ribot, JL; Ramasubramanian, A; Srinivasan, A; Uppuluri, P | 1 |
| Andes, DR; Averette, A; Bigol, UG; Brand, A; Chen, YL; Filler, SG; Heitman, J; Malbas, FF; Morrison, EL; Nett, JE; Silao, FG; Solis, NV | 1 |
| Henriques, M; Lopez-Ribot, JL; Martins, M; Oliveira, R | 1 |
| Castanheira, M; Hata, K; Jones, RN; Messer, SA; Moet, GJ; Pfaller, MA | 1 |
| Garey, KW; Lasco, TM; Palmer, HR; Salazar, M; Shah, DN; Weston, J; Yau, R | 1 |
| Barrios-Fernández, A; Borobia, AM; Carcas, AJ; de la Puente, JM; Frías, J; García-Rodríguez, J; Herrero, A; Lei, S; Ortega, JM; Ramírez, E; Sánchez, M | 1 |
| Meurman, JH; Pärnänen, P; Samaranayake, LP; Seneviratne, CJ; Vaara, M; Wong, SS; Yuen, KY | 1 |
| Lingegowda, PB; Tan, AL; Tan, BH; Tan, CK | 1 |
| Bassetti, M; Molinari, MP; Mussap, M; Nicco, E; Taramasso, L; Viscoli, C | 1 |
| Batoni, G; Del Gaudio, G; Maisetta, G; Petruzzelli, R; Sanguinetti, M; Senesi, S; Tavanti, A | 1 |
| Labbé, AC; Laverdière, M; Levallois, J; Nadeau-Fredette, AC; Ouimet, D; Vallée, M | 1 |
| Alvarez-Lerma, F; Gimeno-Costa, R; Gracia-Arnillas, MP; Insausti-Ordeñana, J; López-Pueyo, MJ; Olaechea-Astigarraga, PM; Otal-Entraigas, JJ; Palomar-Martínez, M; Seijas-Betolaza, I | 1 |
| Bedin, M; D'Angelo, M; Gion, M; Grandesso, S; Mazzuccato, S; Sapino, B; Solinas, M | 1 |
| Ghannoum, MA; Isham, N; Richie, DL; Ryder, NS; Thompson, KV | 1 |
| Alves, SH; Antunes, MS; Bandeira, LA; Denardi, LB; Mario, DA; Santurio, JM; Severo, LC | 1 |
| Bayegan, S; Földi, R; Gesztelyi, R; Juhász, B; Kardos, G; Majoros, L; Szilágyi, J | 1 |
| Chen, TC; Chen, YC; Chen, YH; Lu, PL | 1 |
| Brilhante, RS; Caetano, ÉP; Camargo, ZP; Castelo-Branco, DS; Cordeiro, RA; Fechine, MA; Lima, RA; Mesquita, JR; Monteiro, AJ; Pereira, JF; Rocha, MF; Sidrim, JJ | 1 |
| Brilhante, RS; Castelo-Branco, DS; Cordeiro, RA; Giffoni Leite, JJ; Lima, DT; Monteiro, AJ; Paiva, MA; Rocha, MF; Sidrim, JJ; Teixeira, CE | 1 |
| Ahmed, S; de Hoog, GS; Feng, P; Klaassen, CH; Lai, W; Lu, C; Meis, JF; Najafzadeh, MJ; Sun, J; Xi, L | 1 |
| Berghs, HAM; Carvalho, LR; Kacew, S; Martins, MA; Melhem, MSC; Mendes, RP; Moris, DV; Pimenta-Rodrigues, MV; Souza, LR; Szeszs, MW | 1 |
| de Souza Bonfim-Mendonça, P; Fiorini, A; Godoy, JS; Nakamura, SS; Pieralisi, N; Shinobu-Mesquita, C; Svidzinski, TI; Yamada, SS | 1 |
| Chauhan, NM; Karuppayil, SM; Raut, JS; Shinde, RB | 1 |
| Bujdáková, H; Černáková, L; Kulková, N | 1 |
| Barrs, VR; Houbraken, J; Kidd, SE; Martin, P; Pinheiro, MD; Richardson, M; Samson, RA; van Doorn, TM; Varga, J | 1 |
| Chaudhary, P; Chauhan, VS; Deshpande, M; Maurya, IK; Prasad, R; Sharma, J; Singh, MK; Thakur, IS; Thota, CK; Tupe, SG | 1 |
| Bethlendy, G; Kravets, A; Rustchenko, E; Welle, S; Yang, F | 1 |
| Jorge, JH; Machado, AL; Mima, EG; Pavarina, AC; Sanitá, PV; Vergani, CE | 1 |
| Curfs-Breuker, I; de Hoog, GS; Feng, P; Meis, JF; Najafzadeh, MJ; Rezaei-Matehkolaei, A; Saradeghi Keisari, M; Shamsian, SA; Vicente, VA | 1 |
| Bastide, C; Bruyère, F; Chandenier, J; Desoubeaux, G; Fourcade, C; Guy, L; Karsenty, G; Lachaud, L; Lavigne, JP; Malavaud, S; Sotto, A | 1 |
| Bille, J; Calandra, T; Fehr, J; Garbino, J; Marchetti, O; Mühlethaler, K; Orasch, C; Pfyffer, G; Ruef, C; Schrenzel, J; Zbinden, R; Zimmerli, S | 1 |
| Lopez-Ribot, JL; Pierce, CG; Sarkar, S; Uppuluri, P | 1 |
| Balci, I; Eksi, F; Gayyurhan, ED | 1 |
| Capilla, J; Fothergill, AW; Guarro, J; Pastor, FJ; Sandoval-Denis, M; Sutton, DA | 1 |
| Kunicka-Styczyńska, A; Maroszyńska, I; Maroszyńska, M; Rajkowska, K | 1 |
| Borens, O; Furustrand Tafin, U; Maiolo, EM; Trampuz, A | 1 |
| Arancia, S; Calugi, C; Cassone, A; Cauda, R; De Bernardis, F; Graziani, S; Greco, MC; Guarna, A; Navarra, P; Ragazzoni, E; Sandini, S; Trabocchi, A; Tringali, G | 1 |
| Beldavs, ZG; Bolden, CB; Chiller, TM; Cleveland, AA; Farley, MM; Harrison, LH; Iqbal, N; Kuykendall, RJ; Lockhart, SR; Park, BJ; Pham, CD; Schaffner, W | 1 |
| Cornely, OA; Franke, B; Glossmann, J; Heimann, SM; Kochanek, M; Langebartels, G; Padosch, SA; Reiner, M; Reuter, H; Seifert, H; Stippel, D; Vehreschild, JJ; Vehreschild, MJ; Vierzig, A; Wisplinghoff, H | 1 |
| Bernardo, SM; Chavez-Dozal, A; Jahng, M; Kulkarny, VV; Lee, SA; Parra, KJ; Rane, HS | 1 |
| Bocanegra, R; Duncanson, FP; Everson, MP; Fothergill, AW; Kirkpatrick, WR; McCarthy, DI; Najvar, LK; Olivo, M; Patterson, TF; Wiederhold, NP | 1 |
| Bax, M; Cammue, BP; Cools, TL; Cos, P; De Brucker, K; De Cremer, K; Lanckacker, E; Thevissen, K | 1 |
| Al-Hakami, AM; Assiry, AM; Assiry, MM; Hamid, ME; Jamil, AS; Joseph, MR; Shaker, MA | 1 |
| Benbouzid, S; Elhaj, SA; Garcia, H; Guitard, J; Hennequin, C; Peltier, J; Rondeau, E; Tligui, M | 1 |
| Bom, VL; Brown, NA; de Castro, PA; Goldman, GH; Mariné, M; Ramalho, LN; Winkelstroter, LK | 1 |
| Badali, H; de Hoog, GS; Mashedi, O; Meis, JF; Mohammadi, R | 1 |
| Bressieux-Degueldre, S; Di Bernardo, S; Sekarski, N | 1 |
| Fong, PH; Lee, VH; Seneviratne, CJ; Wong, SS | 1 |
| Akova, M; Bassetti, M; De Waele, JJ; Dimopoulos, G; Kaukonen, KM; Koulenti, D; Lipman, J; Martin, C; Montravers, P; Rello, J; Rhodes, A; Roberts, JA; Sinnollareddy, MG; Starr, T; Wallis, SC | 1 |
| Anstey, C; Fraser, JF; Fung, YL; Ghassabian, S; Mcdonald, CI; Mullany, DV; Roberts, JA; Shekar, K; Wallis, SC | 1 |
| Ellepola, AN; Jayathilake, JA; Khan, ZU; Sharma, PN | 1 |
| Bulanda, M; Jagielski, T; Skóra, M | 1 |
| Chlebicki, MP; Kwa, AL; Lee, W; Liew, YX; Ngan, CC; Tan, AL; Teo, J; Too, IA | 1 |
| Chowdhary, A; Curfs-Breuker, I; de Hoog, GS; Hagen, F; Madrid, H; Meis, JF | 1 |
| Badali, H; Chowdhary, A; de Hoog, GS; Fakhim, H; Khodavaisy, S; Meis, JF | 1 |
| Auzinger, G; Charbonneau, C; Graham, CN; Kantecki, M; Knox, HN; Playford, EG; Schlamm, H; Weinstein, D | 1 |
| Hall, RG; Payne, KD | 1 |
| Deorukhkar, SC; Saini, S | 1 |
| Barnett, AG; Diab, S; Fraser, JF; Fung, YL; Roberts, JA; Shekar, K; Wallis, SC | 1 |
| Bryan, M; Damianos, A; Fisher, BT; Vendetti, N; Zaoutis, TE | 1 |
| Groeneveld, AB; Rijnders, BJ; van der Geest, PJ; Vonk, AG | 1 |
| Aguado, JM; Bodro, M; Carratalá, J; Casafont, F; Cervera, C; Fariñas, C; Fortún, J; Fresco, G; Gavaldá, J; Goikoetxea, J; Len, O; Martín-Dávila, P; Montejo, M; Moreno, A; Muñoz, P; Muriel, A; Pozo, JC; Silva, JT; Torre-Cisneros, J; Vena, A | 1 |
| Casadevall, A; Chatterjee, S; Fernandes, C; Gonçalves, T; Nakouzi-Naranjo, A; Prados-Rosales, R; Silva, BM; Stark, RE; Zuzarte, M | 1 |
| Angkananuwat, C; Bubphawas, M; Muanmai, S; Pesee, S; Sirivan, P; Tanarerkchai, N; Tancharoensukjit, S | 1 |
| Dabrowski, L; Graciano, AL; Kuzmic, B; Lee, JM; Tablizo, MA | 1 |
| Capilla, J; Guarro, J; Martin-Vicente, A; Sanchis, M | 1 |
| Adams, EK; Ashcraft, DS; Pankey, GA | 1 |
| Badrane, H; Clancy, CJ; Nguyen, MH | 1 |
| Baker, GM; Huang, W; Lau, R; Liao, G; Paderu, P; Perlin, DS; Wang, Y; Xue, C | 1 |
| Arslan, U; Dagi, HT; Findik, D; Senkeles, C | 1 |
| Douglas, J; Gassiep, I; Playford, EG | 1 |
| Ahmad, N; Ginsapu, SJ; Gowbei, A; Hashim, R; Ho Betty, LS; Ramli, NY; Razak, MF; Sabaratnam, P; Sipiczki, M; Suppiah, J; Tap, RM | 1 |
| Bocanegra, R; Kadosh, D; Kirkpatrick, WR; Najvar, LK; Olivo, M; Patterson, TF; Wiederhold, NP | 1 |
| Cushion, MT; DiDone, L; Fothergill, AW; Green, J; Halterman, JP; Koselny, K; Krysan, DJ; Patterson, TF; Rappelye, C; Wellington, M; Wiederhold, NP | 1 |
| Chojnicki, M; Haponiuk, I; Irga-Jaworska, N; Jaworski, R; Naumiuk, Ł | 1 |
| Alp, E; Cevahir, F; Ture, Z; Ulu Kilic, A; Yozgat, N | 1 |
| Barber, KE; Cretella, D; King, ST; Stover, KR | 1 |
| Qian, F; Wei, X; Xia, J; Xu, W; Zhang, Z | 1 |
| Arora, A; Capoor, MR; Chakrabarti, A; Chhina, D; Das, S; Ghosh, A; Kaur, H; Kindo, AJ; Marak, RSK; Patel, A; Paul, RA; Rudramurthy, SM; Sardana, R; Singh, P; Sood, P; Tarai, B; Xess, I | 1 |
| Arthur, I; Baird, R; Bak, N; Blyth, C; Botes, J; Chapman, B; Chen, S; Cheong, E; Cooley, L; George, CR; Goeman, E; Hajkowicz, K; Halliday, C; Heath, CH; Hofmeyr, A; Kalukottege, P; Keighley, C; Kennedy, K; Kesson, A; Kidd, S; Korman, TM; Leung, M; Liu, E; Macesic, N; Marriott, D; McMullan, B; Morrissey, CO; Pendle, S; Robson, J; Slavin, M; Sorrell, TC; Underwood, N; van Hal, S; Weeks, K | 1 |
| Alencar, LP; Bittencourt, PV; Brilhante, RSN; de Aguiar Cordeiro, R; de Aquino Pereira-Neto, W; de Melo Guedes, GM; de Oliveira, JS; de Souza Collares Castelo-Branco, D; Nogueira-Filho, EF; Pinheiro, M; Rocha, MFG; Sidrim, JJC | 1 |
| Budzyńska, A; Różalska, B; Sadowska, B; Stochmal, A; Żuchowski, J | 1 |
| Bairy, I; Baral, BP; Gokhale, S; Hamal, D; Nayak, N; Prakash, PY; Sathian, B; Sharan, NK; Subramanya, SH | 1 |
| Charbonneau, C; Chen, YC; Lee, TY; Ou, HT | 1 |
| Badali, H; Chowdhary, A; Dannaoui, E; Fakhim, H; Meis, JF; Prakash, A; Vaezi, A | 1 |
| Hsueh, PR; Hung, YL; Ko, WC; Lai, CC; Li, MC; Liu, WL; Tang, HJ; Wu, CJ | 1 |
| Chen, L; Dong, W; Dong, Y; Li, Y; Meng, T; Wang, X; Wang, Y; Xie, J; Xing, Y | 1 |
| Badali, H; Badiee, P; Boekhout, T; Diba, K; Hossaini Nasab, A; Jafarian, H; Mirhendi, H; Moghadam, AG; Mohammadi, R; Najafzadeh, MJ; Shamsizadeh, A; Soltani, J | 1 |
| Kang, M; Liu, Y; Lv, X; Ye, H; Zong, Z | 1 |
| Ahangarkani, F; Aslani, N; Badali, H; Boekhout, T; Hagen, F; Kolecka, A; Meis, JF; Meyabadi, MF; Shokohi, T | 1 |
| Honda, A; Ikeda, M; Koya, J; Kurokawa, M; Misawa, Y; Morita, K; Moriya, K; Nakamura, F; Okugawa, S; Toyama, K | 1 |
| Freeman, JT; McKinney, WP; Morris, AJ; Roberts, SA; Rogers, K | 1 |
| Kooshki, P; Mahmoudabadi, AZ; Rezaei-Matehkolaei, A | 1 |
| Brilhante, RSN; Castelo-Branco, DSCM; Cordeiro, RA; Guedes, GMM; Rocha, MFG; Sidrim, JJC; Silva, MLQD | 1 |
| Hadian, A; Mohamadnia, A; Mortezaee, V; Rezaie, S; Seyedmousavi, S; Sharifynia, S | 1 |
| Chiang, MC; Chu, SM; Fu, RH; Hsu, JF; Huang, HR; Lai, MY; Lee, CW; Lee, IT; Tsai, MH; Wu, IH | 1 |
| Bing, J; Du, H; Huang, G; Liu, J; Tao, L; Wang, H; Wang, X; Wang, Y; Yue, H; Zhang, F; Zheng, Q | 1 |
| Abebaw, Y; Bitew, A | 1 |
| Feinstein, A; Perez, IE; Stein, DK; Sung, J | 1 |
| Falahati, M; Farahyar, S; Hadighi, R; Kalantari, S; Khedri, S; Khoshmirsafa, M; Roudbary, M; Santos, ALS | 1 |
| Challa, K; Edlind, T; Katiyar, S | 1 |
| Lehrnbecher, T; Schmidt, S; Schubert, R; Tramsen, L | 1 |
| Kader, NA; Patil, S; Raj, AT; Seetharam, C; Sujatha, G | 1 |
| Eraso, E; Gil-Alonso, S; Jauregizar, N; Marcos-Arias, C; Mateo, E; Quindós, G; Sevillano, E | 1 |
| Ataollahy, N; Hammarström, H; Kondori, N; Lindberg, E | 1 |
| Arastehfar, A; Boekhout, T; Brouwer, C; Charsizadeh, A; Daneshnia, F; Haas, PJ; Hagen, F; Khodavaisy, S; Najafzadeh, MJ; Pan, W; Roudbary, M; Salehi, MR; Zarrinfar, H; Zomorodian, K | 1 |
| Chaftari, AM; Hachem, R; Kontoyiannis, DP; Raad, II; Reitzel, RA; Rosenblatt, J; Vargas-Cruz, N; Wilson Dib, R | 1 |
| Bolon, MK; Clark, J; Gilley, JH; Kadakia, AR; Ko, JH; Roberts, SC; Taiwo, BO; Ward-Fore, S; Zembower, TR | 1 |
| Altintop, YA; Atalay, MA; Ergul, AB; Koc, AN | 1 |
| Alexander, S; Callahan, C; Chen, L; Dang, H; Dvorak, CC; Esbenshade, AJ; Fisher, BT; Nieder, M; Sung, L; Villaluna, D; Wiley, JM; Wingard, JR; Zaoutis, T; Zerr, D | 1 |
| Gupta, MK; Pandey, N; Paul, P; Tilak, R | 1 |
| Argaud, L; Aubrun, F; Bienvenu, AL; Chidiac, C; Fellahi, JL; Friggeri, A; Guerin, C; Guichon, C; Hernu, R; Leboucher, G; Menotti, J; Monard, C; Paulus, S; Piriou, V; Pradat, P; Rimmele, T | 1 |
| Brüggemann, RJM; de Lange, DW | 1 |
| Alteri, C; Bielli, A; Brioschi, P; Cairoli, R; Cento, V; Colombo, J; De Gasperi, A; Gasparini, LE; Gatti, M; Lepera, V; Lombardi, G; Mancini, V; Mazza, E; Merli, M; Moioli, MC; Orcese, CA; Perno, CF; Puoti, M; Torri, S; Vismara, C | 1 |
| Chen, FJ; Chen, IL; Chen, YC; Chien, CC; Lee, CH | 1 |
| Gharaghani, M; Taghipour, S; Zarei Mahmoudabadi, A | 1 |
| Chen, J; Chu, Y; Han, X; Shang, H; Tian, S; Wang, Q; Zhou, B | 1 |
| Cao, S; Ding, C; Wang, R; Xia, M; Zhu, X | 1 |
| Chen, FJ; Chen, YC; Lee, CH | 1 |
| Berkow, EL; Damm, T; Lockhart, SR; Nunnally, NS | 1 |
| Amanati, A; Badiee, P; Ghasemi, F; Haghpanah, S; Hamzavi, SS; Jafarian, H; Nematolahi, S | 1 |
| Farooqi, J; Jabeen, K; Memon, S; Naqvi, SF; Zafar, A; Zafar, U | 1 |
| Liu, L; Tu, Y; Xu, T; Yuan, G | 1 |
| Atiencia-Carrera, MB; Cabezas-Mera, FS; Machado, A; Tejera, E | 1 |
| Cho, SI; Choi, SH; Kim, J; Kim, SY; Kim, WJ; Kim, YR; Koo, J; Lee, CH; Lee, H; Lee, HJ; Lee, HK; Oh, J; Ryu, SW; Shin, JH; Sohn, YH; Sung, GH | 1 |
| Amiri, S; Erami, M; Fakhrehi, M; Getso, MI; Hashemi, SJ; Mehri, N; Momen-Heravi, M; Raiesi, O; Raissi, V; Yarahmadi, M | 1 |
| Ameye, L; Aoun, M; Barnes, R; Baron, F; Bertz, H; Blijlevens, N; Bochud, PY; Chantepie, S; Cheung, KJ; Coiteux, V; Cordonnier, C; Donnelly, JP; Drgona, L; Heinz, WJ; Hepler, DA; Lamoth, F; Llorente, CC; Lodewyck, T; Loeffler, J; Maertens, J; Marchetti, O; Meert, L; Paesmans, M; Ráčil, Z; Robin, C; Schaefer-Prokop, C; Schwarzinger, M; Selleslag, D; Turlure, P; Vandercam, B; Verweij, P | 1 |
| Dong, Y; Liu, Z; Wang, Y; Wang, YF; Xie, J; Yang, Q; Zhang, K | 1 |
| Kim, HR; Kim, TH; Kweon, OJ; Lee, MK; Lim, YK | 1 |
| Abebe, W; Alemayehu, T; Ali, EE; Erku, DA; Fentie, AM; Gebremariam, GT; Gebretekle, GB; Sander, B | 1 |
| An, R; Chen, Y; Cui, F; Cui, M; Fan, S; Kan, S; Li, D; Li, P; Li, X; Liang, X; Liao, Q; Liu, W; Lv, G; Mei, H; Pang, Q; Qiao, Q; Song, N; Xiong, Z; Zhang, M; Zheng, H | 1 |
| Balázs, B; Balogh, B; Bozó, A; Forgács, L; Kelentey, B; Kovács, R; Majoros, L; Tóth, Z | 1 |
| Li, J; Sun, S; Wang, Y; Wang, Z; Yan, H; Zhang, Y | 1 |
| Amin Shahidi, M; Badiee, P; Ghasemi, F; Hashemi, J; Jafarian, H; Mohammadi, R; Najafzadeh, MJ; Shokohi, T | 1 |
| Anversa, L; Arnoni, MV; Auler, M; Bonfietti, LX; de Camargo, BB; Dias, ALT; Garces, HG; Gimenes, VMF; Lara, BR; Leite Junior, DP; Melhem, MSC; Monari, GPM; Moreira, D; Oliveira, L; Paula, CR; Ramos, RTB; Richini-Pereira, VB; Ruiz, LDS; Silva, NC; Silveira, M | 1 |
| Charkhchian, M; Mirzadeh, M; Mohammadi, F | 1 |
| Cappuccinelli, P; Do, TBT; Fiamma, M; Ngo, TMC; Paglietti, B; Santona, A; Ton Nu, PA | 1 |
| He, C; Kang, W; Li, J; Wang, T; Xu, Y; Yu, J; Zhang, G; Zhang, J; Zhao, Y | 1 |
| Abdorahimi, M; Ahmadikia, K; Badali, H; Gharehbolagh, SA; Khodavaisy, S; Mahmoudi, S; Meis, JF; Rezaie, S | 1 |
27 review(s) available for fluconazole and l 743,872
| Article | Year |
|---|---|
[Clinical relevance of mechanisms of antifungal drug resistance in filamentous fungi].
Topics: Amphotericin B; Anti-Bacterial Agents; Antifungal Agents; Azoles; Caspofungin; Drug Resistance, Fungal; Drug Resistance, Multiple; Echinocandins; Fluconazole; Fungi; Incidence; Itraconazole; Lipopeptides; Mycoses; Naphthalenes; Peptides; Peptides, Cyclic; Polyenes; Spain; Terbinafine | 2002 |
[Antifungal drug].
Topics: Amphotericin B; Anti-Bacterial Agents; Antifungal Agents; Azoles; Caspofungin; Drug Design; Drug Resistance, Fungal; Echinocandins; Fluconazole; Fluorouracil; Fungi; Humans; Itraconazole; Lipopeptides; Lipoproteins; Micafungin; Mycoses; Opportunistic Infections; Peptides; Peptides, Cyclic; Polyenes; Pyrimidines | 2003 |
Update on antifungal therapy.
Topics: Amphotericin B; Animals; Anti-Bacterial Agents; Antifungal Agents; Caspofungin; Cat Diseases; Cats; Dog Diseases; Dogs; Echinocandins; Fluconazole; Itraconazole; Lipopeptides; Mycoses; Naphthalenes; Peptides; Peptides, Cyclic; Terbinafine | 2003 |
Antifungal pharmacotherapy for neonatal candidiasis.
Topics: Amphotericin B; Antifungal Agents; Candidiasis; Caspofungin; Cross Infection; Echinocandins; Fluconazole; Flucytosine; Fungal Proteins; Fungemia; Humans; Infant, Newborn; Infant, Premature; Intensive Care Units, Neonatal; Ketoconazole; Lipopeptides; Peptides; Peptides, Cyclic; Pyrimidines; Triazoles; Voriconazole | 2003 |
[New therapeutical options for pulmonary fungal infections in non-neutropenic ICU-patients].
Topics: Amphotericin B; Antifungal Agents; Caspofungin; Echinocandins; Fluconazole; Fungi; Humans; Intensive Care Units; Lipopeptides; Lung Diseases, Fungal; Neutropenia; Peptides; Peptides, Cyclic; Pyrimidines; Risk Factors; Triazoles; Voriconazole | 2003 |
[New developments in antifungal therapy: fluconazole, itraconazole, voriconazole, caspofungin].
Topics: Amphotericin B; Antifungal Agents; Caspofungin; Drug Carriers; Echinocandins; Fluconazole; Humans; Itraconazole; Lipopeptides; Mycoses; Peptides; Peptides, Cyclic; Pyrimidines; Species Specificity; Treatment Outcome; Triazoles; Voriconazole | 2004 |
Combination antifungal therapy: where are we now, and where are we going?
Topics: Amphotericin B; Animals; Antifungal Agents; Aspergillosis; Azoles; Candidiasis; Caspofungin; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Echinocandins; Fluconazole; Humans; In Vitro Techniques; Lipopeptides; Lipoproteins; Micafungin; Mycoses; Peptides, Cyclic; Pyrimidines; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Triazoles; Voriconazole | 2004 |
Antifungal resistance: the clinical front.
Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis; Caspofungin; Drug Resistance, Fungal; Echinocandins; Fluconazole; Health Status; Humans; Lipopeptides; Peptides, Cyclic; Pyrimidines; Risk Factors; Thiazoles; Treatment Outcome; Triazoles; United States; Voriconazole | 2004 |
Antifungal agents in children.
Topics: Age Factors; Amphotericin B; Anidulafungin; Antifungal Agents; Caspofungin; Chemistry, Pharmaceutical; Child; Clinical Trials as Topic; Drug Approval; Drug Resistance, Fungal; Echinocandins; Fluconazole; Flucytosine; Humans; Itraconazole; Lipopeptides; Lipoproteins; Micafungin; Mycoses; Patient Selection; Pediatrics; Peptides, Cyclic; Pyrimidines; Safety; Thiazoles; Triazoles; United States; Voriconazole | 2005 |
Voriconazole: review of a broad spectrum triazole antifungal agent.
Topics: Administration, Oral; Animals; Antifungal Agents; Aspergillosis; Candidiasis; Caspofungin; Cryptococcosis; Cyclic N-Oxides; Disease Models, Animal; Drug Resistance, Fungal; Drug Therapy, Combination; Echinocandins; Fluconazole; Humans; Injections, Intravenous; Lipopeptides; Microbial Sensitivity Tests; Mycoses; Peptides, Cyclic; Pyrimidines; Randomized Controlled Trials as Topic; Triazoles; Voriconazole | 2005 |
Drug-drug interactions of antifungal agents and implications for patient care.
Topics: Acidosis, Renal Tubular; Amphotericin B; Antifungal Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biotransformation; Caspofungin; Clinical Trials as Topic; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Therapy, Combination; Echinocandins; Enzyme Inhibitors; Fluconazole; Humans; Itraconazole; Lipopeptides; Liver; Mycoses; Patient Care; Peptides, Cyclic | 2005 |
Candida glabrata prosthetic valve endocarditis treated successfully with fluconazole plus caspofungin without surgery: a case report and literature review.
Topics: Acute Kidney Injury; Aged; Amphotericin B; Antifungal Agents; Candida glabrata; Candidiasis; Caspofungin; Drug Therapy, Combination; Echinocandins; Endocarditis; Fluconazole; Heart Valve Prosthesis; Humans; Lipopeptides; Male; Mitral Valve; Peptides, Cyclic; Prosthesis-Related Infections | 2005 |
Fungal infections in solid organ transplantation.
Topics: Amphotericin B; Antifungal Agents; Aspergillosis; Candidiasis; Caspofungin; Clinical Trials as Topic; Cryptococcosis; Deoxycholic Acid; Drug Combinations; Echinocandins; Fluconazole; Humans; Incidence; Lipopeptides; Organ Transplantation; Peptides, Cyclic; Postoperative Complications; Premedication | 2006 |
Treatment of invasive candidal infections: systematic review and meta-analysis.
Topics: Amphotericin B; Antifungal Agents; Candidiasis; Caspofungin; Confidence Intervals; Drug Therapy, Combination; Echinocandins; Fluconazole; Humans; Itraconazole; Lipopeptides; Lipoproteins; Micafungin; Odds Ratio; Pyrimidines; Treatment Outcome; Triazoles; Voriconazole | 2008 |
Successful intensive chemotherapy followed by autologous hematopoietic cell transplantation in a patient with acute myeloid leukemia and hepatosplenic candidiasis: case report and review of literature.
Topics: Adult; Antifungal Agents; Candida tropicalis; Candidiasis; Caspofungin; Cytarabine; Echinocandins; Female; Fluconazole; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Lipopeptides; Liver Diseases; Radiography; Splenic Diseases; Tomography Scanners, X-Ray Computed | 2009 |
Mycotic pulmonary artery aneurysm due to Aspergillus infection in a patient with leukemia: case report and review of the literature.
Topics: Abscess; Acyclovir; Amphotericin B; Aneurysm, Infected; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Agents; Antiviral Agents; Aspergillus; Caspofungin; Ceftazidime; Clindamycin; Echinocandins; Fluconazole; Humans; Leukemia, Hairy Cell; Lipopeptides; Male; Middle Aged; Mouth; Ofloxacin; Pneumonia; Pulmonary Artery; Pulmonary Aspergillosis; Valacyclovir; Valine; Vancomycin | 2010 |
Traditional and emerging antifungal therapies.
Topics: Amphotericin B; Anidulafungin; Antifungal Agents; Caspofungin; Drug Therapy, Combination; Echinocandins; Fluconazole; Humans; Itraconazole; Lipopeptides; Micafungin; Pyrimidines; Triazoles; Voriconazole | 2010 |
Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.
Topics: Anidulafungin; Antifungal Agents; beta-Glucans; Candida; Candidiasis; Caspofungin; Drug Resistance, Fungal; Echinocandins; Fluconazole; Glucosyltransferases; Humans; Inhibitory Concentration 50; Lipopeptides; Micafungin; Microbial Sensitivity Tests; Mutation; Proteoglycans; Randomized Controlled Trials as Topic; Species Specificity; Treatment Outcome | 2011 |
In vitro activity of echinocandins against non-Candida albicans: is echinocandin antifungal activity the same?
Topics: Anidulafungin; Candida; Candidiasis; Caspofungin; Drug Evaluation, Preclinical; Drug Resistance, Fungal; Drug Resistance, Multiple, Fungal; Echinocandins; Fluconazole; Fungal Proteins; Glucosyltransferases; Humans; In Vitro Techniques; Lipopeptides; Micafungin; Microbial Sensitivity Tests; Species Specificity; Therapeutic Equivalency | 2011 |
Ten-year experience with fungal peritonitis in peritoneal dialysis patients: antifungal susceptibility patterns in a North-American center.
Topics: Adult; Aged; Amphotericin B; Antifungal Agents; Candida; Caspofungin; Drug Resistance, Fungal; Echinocandins; Female; Fluconazole; Follow-Up Studies; Humans; Itraconazole; Lipopeptides; Male; Micafungin; Microbial Sensitivity Tests; Middle Aged; Mycoses; North America; Peritoneal Dialysis; Peritonitis; Pyrimidines; Triazoles; Voriconazole | 2012 |
[Non-antibiotic anti-infectious treatments in urology].
Topics: Acyclovir; Albendazole; Amphotericin B; Anti-Infective Agents; Caspofungin; Cidofovir; Cytosine; Echinocandins; Fluconazole; Flucytosine; Foscarnet; Ganciclovir; Humans; Ivermectin; Lipopeptides; Organophosphonates; Praziquantel; Urologic Diseases; Valganciclovir | 2013 |
Dosing of antifungal agents in obese people.
Topics: Amphotericin B; Antifungal Agents; Candidiasis, Invasive; Caspofungin; Echinocandins; Fluconazole; Humans; Lipopeptides; Micafungin; Mycoses; Nitriles; Obesity; Pyridines; Triazoles | 2016 |
Choosing Optimal Antifungal Agents To Prevent Fungal Infections in Nonneutropenic Critically Ill Patients: Trial Sequential Analysis, Network Meta-analysis, and Pharmacoeconomic Analysis.
Topics: Antifungal Agents; Caspofungin; Cost-Benefit Analysis; Critical Illness; Echinocandins; Economics, Pharmaceutical; Fluconazole; Humans; Invasive Fungal Infections; Lipopeptides; Micafungin; Network Meta-Analysis; Primary Prevention | 2017 |
Therapeutic tools for oral candidiasis: Current and new antifungal drugs.
Topics: Administration, Intravenous; Administration, Oral; Administration, Topical; Amphotericin B; Anidulafungin; Antifungal Agents; Azoles; Candidiasis, Oral; Caspofungin; Clotrimazole; Databases, Factual; Drug Interactions; Echinocandins; Fluconazole; Humans; Miconazole; Nitriles; Nystatin; Pyridines; Triazoles | 2019 |
Molecular characterization and antifungal susceptibility testing of Candida nivariensis from blood samples - an Iranian multicentre study and a review of the literature.
Topics: Adolescent; Aged; Amphotericin B; Amplified Fragment Length Polymorphism Analysis; Antifungal Agents; Bronchoalveolar Lavage; Candida; Candidemia; Candidiasis; Caspofungin; DNA, Intergenic; Fatal Outcome; Female; Fluconazole; Genotype; Humans; Iran; Male; Microbial Sensitivity Tests; Middle Aged; Polymerase Chain Reaction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Vagina; Voriconazole | 2019 |
Is the superbug fungus really so scary? A systematic review and meta-analysis of global epidemiology and mortality of Candida auris.
Topics: Amphotericin B; Anidulafungin; Antifungal Agents; Candida; Candidiasis; Caspofungin; Drug Resistance, Multiple, Fungal; Fluconazole; Humans; Micafungin; Prevalence | 2020 |
Prevalence of biofilms in Candida spp. bloodstream infections: A meta-analysis.
Topics: Biofilms; Candida; Candidemia; Candidiasis; Caspofungin; Drug Resistance, Fungal; Fluconazole; Hospitalization; Humans; Prevalence; Sepsis; Voriconazole | 2022 |
5 trial(s) available for fluconazole and l 743,872
| Article | Year |
|---|---|
A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis.
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Antifungal Agents; Candidiasis, Oral; Caspofungin; Chile; Double-Blind Method; Drug Administration Schedule; Echinocandins; Esophagitis; Esophagoscopy; Female; Fluconazole; Guatemala; Humans; Infusions, Intravenous; Lipopeptides; Male; Middle Aged; Pennsylvania; Peptides; Peptides, Cyclic; Peru; Treatment Outcome | 2002 |
Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole.
Topics: Adult; Anti-Bacterial Agents; Antifungal Agents; Candida; Candidiasis; Caspofungin; Cohort Studies; Dose-Response Relationship, Drug; Drug Resistance, Fungal; Echinocandins; Esophageal Diseases; Esophagoscopy; Female; Fluconazole; Humans; Infusions, Parenteral; Lipopeptides; Male; Microbial Sensitivity Tests; Middle Aged; Peptides; Peptides, Cyclic; Retrospective Studies; Treatment Outcome | 2002 |
Caspofungin in kidney transplant recipients with refractory invasive candidiasis.
Topics: Antifungal Agents; Candidiasis; Caspofungin; Drug Resistance, Fungal; Echinocandins; Esophagus; Fluconazole; Humans; Kidney Transplantation; Lipopeptides; Opportunistic Infections; Peptides, Cyclic; Urinary Tract | 2007 |
Effect of Caspofungin vs Fluconazole Prophylaxis on Invasive Fungal Disease Among Children and Young Adults With Acute Myeloid Leukemia: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Antifungal Agents; Aspergillosis; Caspofungin; Child; Child, Preschool; Early Termination of Clinical Trials; Female; Fluconazole; Humans; Infant; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Mycoses; Neutropenia; Young Adult | 2019 |
Empiric vs Preemptive Antifungal Strategy in High-Risk Neutropenic Patients on Fluconazole Prophylaxis: A Randomized Trial of the European Organization for Research and Treatment of Cancer.
Topics: Antifungal Agents; Caspofungin; Fluconazole; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Mycoses; Myelodysplastic Syndromes | 2023 |
221 other study(ies) available for fluconazole and l 743,872
| Article | Year |
|---|---|
Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro.
Topics: Amphotericin B; Anti-Bacterial Agents; Antifungal Agents; Caspofungin; Cell Line; Cell Survival; Cryptococcus neoformans; Drug Resistance, Microbial; Drug Synergism; Echinocandins; Fluconazole; Humans; Lipopeptides; Microbial Sensitivity Tests; Peptides; Peptides, Cyclic | 1997 |
Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans.
Topics: Anidulafungin; Anti-Bacterial Agents; Antifungal Agents; Candida; Caspofungin; Cryptococcus neoformans; Echinocandins; Fluconazole; Lipopeptides; Microbial Sensitivity Tests; Peptides; Peptides, Cyclic; Solubility; Solvents | 1997 |
Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp.
Topics: Amphotericin B; Anidulafungin; Anti-Bacterial Agents; Antifungal Agents; Blood; Candida; Caspofungin; Echinocandins; Fluconazole; Flucytosine; Humans; Itraconazole; Lipopeptides; Peptides; Peptides, Cyclic; Sensitivity and Specificity; Serum Bactericidal Test | 1998 |
In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Anti-Bacterial Agents; Antifungal Agents; Candida; Candidiasis; Caspofungin; Echinocandins; Fluconazole; Flucytosine; Humans; Itraconazole; Lipopeptides; Microbial Sensitivity Tests; Peptides; Peptides, Cyclic; Pyrimidines; Thiazoles; Triazoles; Voriconazole | 1999 |
Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans.
Topics: Anti-Bacterial Agents; Antifungal Agents; Calcineurin; Calcineurin Inhibitors; Caspofungin; Cryptococcus neoformans; Drug Combinations; Drug Synergism; Echinocandins; Fluconazole; Humans; Immunophilins; Lipopeptides; Macrolides; Microbial Sensitivity Tests; Peptides; Peptides, Cyclic; Tacrolimus; Tacrolimus Binding Proteins | 2000 |
Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans.
Topics: Amphotericin B; Anidulafungin; Anti-Bacterial Agents; Antifungal Agents; Azoles; Candida albicans; Caspofungin; Cryptococcus neoformans; Echinocandins; Fluconazole; Lipopeptides; Microbial Sensitivity Tests; Peptides; Peptides, Cyclic; Polyenes | 2000 |
In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance.
Topics: AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Antifungal Agents; Azoles; Candida albicans; Candidiasis, Oral; Caspofungin; Drug Resistance, Fungal; Echinocandins; Fluconazole; Fungal Proteins; Humans; Lipopeptides; Microbial Sensitivity Tests; Peptides; Peptides, Cyclic | 2002 |
Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods.
Topics: Anidulafungin; Anti-Bacterial Agents; Antifungal Agents; Candida; Caspofungin; Cell Division; Cryptococcus neoformans; Drug Resistance, Multiple, Fungal; Drug Therapy, Combination; Echinocandins; Fluconazole; Humans; Lipopeptides; Logistic Models; Microbial Sensitivity Tests; Peptides; Peptides, Cyclic; Time Factors | 2002 |
Breakthrough trichosporonosis in a bone marrow transplant recipient receiving caspofungin acetate.
Topics: Adult; Amphotericin B; Anti-Bacterial Agents; Antifungal Agents; Aspergillosis; Bone Marrow Transplantation; Caspofungin; Chemoprevention; Drug Therapy, Combination; Echinocandins; Fluconazole; Humans; Lipopeptides; Male; Mycoses; Opportunistic Infections; Peptides; Peptides, Cyclic; Trichosporon | 2002 |
In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies.
Topics: Amphotericin B; Anti-Bacterial Agents; Antifungal Agents; Biofilms; Candida albicans; Caspofungin; Colony Count, Microbial; Colorimetry; Coloring Agents; Echinocandins; Fluconazole; Indicators and Reagents; Lipopeptides; Peptides; Peptides, Cyclic; Reproducibility of Results; Tetrazolium Salts; Time Factors | 2002 |
In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates.
Topics: Anti-Bacterial Agents; Antifungal Agents; Candida; Candidiasis; Caspofungin; Drug Resistance, Fungal; Echinocandins; Fluconazole; Humans; Itraconazole; Lipopeptides; Microbial Sensitivity Tests; Peptides; Peptides, Cyclic; Quality Control | 2003 |
Caspofungin versus amphotericin B for invasive candidiasis.
Topics: Amphotericin B; Anti-Bacterial Agents; Antifungal Agents; Candidiasis; Caspofungin; Drug Resistance, Fungal; Echinocandins; Fluconazole; Humans; Lipopeptides; Peptides; Peptides, Cyclic | 2003 |
Successful treatment of Candida krusei infection with caspofungin acetate: a new antifungal agent.
Topics: Adult; Amphotericin B; Anti-Bacterial Agents; Antifungal Agents; Candida; Candidiasis; Caspofungin; Echinocandins; Fluconazole; Fungemia; Humans; Infusions, Intravenous; Lipopeptides; Male; Neutropenia; Opportunistic Infections; Peptides; Peptides, Cyclic; Pleural Effusion; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
Addition of caspofungin to fluconazole does not improve outcome in murine candidiasis.
Topics: Animals; Anti-Bacterial Agents; Antifungal Agents; Candidiasis; Caspofungin; Drug Therapy, Combination; Echinocandins; Fluconazole; Lipopeptides; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Peptides; Peptides, Cyclic | 2003 |
Antifungal combinations against Candida albicans biofilms in vitro.
Topics: Amphotericin B; Antifungal Agents; Biofilms; Candida albicans; Caspofungin; Drug Combinations; Echinocandins; Fluconazole; Lipopeptides; Peptides; Peptides, Cyclic; Tetrazolium Salts | 2003 |
Caspofungin activity against clinical isolates of fluconazole-resistant Candida.
Topics: Antifungal Agents; Candida; Candida albicans; Candida glabrata; Caspofungin; Drug Resistance, Microbial; Echinocandins; Fluconazole; Humans; Lipopeptides; Microbial Sensitivity Tests; Peptides; Peptides, Cyclic | 2003 |
Caspofungin modulates in vitro adherence of Candida albicans to plastic coated with extracellular matrix proteins.
Topics: Antifungal Agents; Biofilms; Candida albicans; Caspofungin; Drug Resistance, Multiple, Fungal; Echinocandins; Extracellular Matrix Proteins; Fluconazole; Implants, Experimental; Lipopeptides; Peptides; Peptides, Cyclic; Plastics; Polystyrenes | 2004 |
Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species.
Topics: Antifungal Agents; Aspergillus; Candida; Caspofungin; Echinocandins; Fluconazole; Geography; Humans; Laboratories; Lipopeptides; Microbial Sensitivity Tests; Peptides; Peptides, Cyclic; Quality Control; Reproducibility of Results | 2004 |
Sequential therapy with caspofungin and fluconazole for Candida albicans infection.
Topics: Animals; Antifungal Agents; Candida albicans; Candidiasis; Caspofungin; Colony Count, Microbial; Drug Therapy, Combination; Echinocandins; Fluconazole; Humans; Kidney; Lipopeptides; Male; Mice; Peptides, Cyclic | 2004 |
Failure of caspofungin to treat brain abscesses secondary to Candida albicans prosthetic valve endocarditis.
Topics: Adult; Amphotericin B; Antifungal Agents; Brain Abscess; Candida albicans; Candidiasis; Caspofungin; Echinocandins; Endocarditis; Fluconazole; Heart Valve Prosthesis; Humans; Lipopeptides; Male; Peptides, Cyclic; Treatment Failure | 2004 |
In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies.
Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis; Caspofungin; Colony Count, Microbial; Echinocandins; Fluconazole; Hematologic Neoplasms; Humans; Kinetics; Lipopeptides; Microbial Sensitivity Tests; Models, Biological; Peptides, Cyclic; Pyrimidines; Triazoles; Voriconazole | 2004 |
Need for early antifungal treatment confirmed in experimental disseminated Candida albicans infection.
Topics: Amphotericin B; Animals; Antifungal Agents; Brain; Candidiasis; Caspofungin; Colony-Forming Units Assay; Echinocandins; Female; Fluconazole; Injections, Intraperitoneal; Lipopeptides; Mice; Mice, Inbred BALB C; Peptides, Cyclic; Survival Analysis; Treatment Outcome | 2004 |
[Treatment with caspofungin of Candida tropicalis endocarditis resistant to fluconazol].
Topics: Aged; Antifungal Agents; Candida tropicalis; Candidiasis; Caspofungin; Drug Resistance, Fungal; Echinocandins; Endocarditis; Fatal Outcome; Fluconazole; Humans; Lipopeptides; Male; Peptides, Cyclic | 2004 |
Evaluation of Mycograb, amphotericin B, caspofungin, and fluconazole in combination against Cryptococcus neoformans by checkerboard and time-kill methodologies.
Topics: Amphotericin B; Antibodies, Fungal; Antifungal Agents; Caspofungin; Cryptococcus neoformans; Dose-Response Relationship, Drug; Drug Therapy, Combination; Echinocandins; Fluconazole; HSP90 Heat-Shock Proteins; Humans; Lipopeptides; Microbial Sensitivity Tests; Nitric Oxide; Peptides, Cyclic; Recombinant Proteins | 2005 |
Caspofungin: a new therapeutic option for fungal endocarditis.
Topics: Adult; Antifungal Agents; Candidiasis; Caspofungin; Echinocandins; Endocarditis; Fluconazole; Humans; Lipopeptides; Male; Peptides, Cyclic | 2005 |
In vitro activity of caspofungin compared to amphotericin B, fluconazole, and itraconazole against Candida strains isolated in a Turkish University Hospital.
Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis; Caspofungin; Echinocandins; Fluconazole; Hospitals, University; Itraconazole; Lipopeptides; Microbial Sensitivity Tests; Peptides, Cyclic; Turkey | 2005 |
In vitro susceptibility of 15 strains of zygomycetes to nine antifungal agents as determined by the NCCLS M38-A microdilution method.
Topics: Antifungal Agents; Caspofungin; Drug Resistance, Fungal; Echinocandins; Fluconazole; Flucytosine; Lipopeptides; Microbial Sensitivity Tests; Mucorales; Peptides, Cyclic | 2005 |
Anti-metabolic activity of caspofungin against Candida albicans and Candida parapsilosis biofilms.
Topics: Antifungal Agents; Antimetabolites; Biofilms; Candida; Candida albicans; Caspofungin; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Fungal; Echinocandins; Fluconazole; Lipopeptides; Microbial Sensitivity Tests; Peptides, Cyclic | 2005 |
Caspofungin susceptibility testing of Candida inconspicua: correlation of different methods with the minimal fungicidal concentration.
Topics: Antifungal Agents; Candida; Caspofungin; Dose-Response Relationship, Drug; Drug Resistance, Fungal; Echinocandins; Fluconazole; Humans; Lipopeptides; Microbial Sensitivity Tests; Peptides, Cyclic | 2005 |
In vitro interaction of posaconazole and caspofungin against clinical isolates of Candida glabrata.
Topics: Antifungal Agents; Candida glabrata; Candidiasis, Oral; Caspofungin; Drug Resistance, Fungal; Drug Synergism; Echinocandins; Fluconazole; Humans; Lipopeptides; Microbial Sensitivity Tests; Peptides, Cyclic; Triazoles | 2005 |
Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Aspergillosis; Aspergillus; Biological Evolution; Calcineurin; Calcineurin Inhibitors; Candida albicans; Candidiasis; Caspofungin; Cyclophilin A; Drug Resistance, Fungal; Echinocandins; Ergosterol; Fluconazole; HSP90 Heat-Shock Proteins; Humans; Lipopeptides; Mutation; Peptides, Cyclic; Phenotype; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Selection, Genetic | 2005 |
Breakthrough Candida krusei fungemia during fluconazole prophylaxis followed by breakthrough zygomycosis during caspofungin therapy in a patient with severe aplastic anemia who underwent stem cell transplantation.
Topics: Adolescent; Anemia, Aplastic; Antifungal Agents; Candida; Candidiasis; Caspofungin; Chemoprevention; Echinocandins; Fatal Outcome; Female; Fluconazole; Fungemia; Fungi; Humans; Lipopeptides; Peptides, Cyclic; Stem Cell Transplantation; Zygomycosis | 2005 |
Experience with caspofungin in the treatment of persistent fungemia in neonates.
Topics: Amphotericin B; Antifungal Agents; Candidiasis; Caspofungin; Drug Therapy, Combination; Echinocandins; Female; Fluconazole; Flucytosine; Fungemia; Gestational Age; Humans; Infant, Newborn; Infant, Premature, Diseases; Infant, Very Low Birth Weight; Intensive Care, Neonatal; Lipopeptides; Male; Peptides, Cyclic; Retrospective Studies | 2005 |
[Economic evaluation of the treatment of systemic fungal infections in immunocompromised patients: the role of itraconazole].
Topics: Amphotericin B; Antifungal Agents; Caspofungin; Echinocandins; Fluconazole; Humans; Immunocompromised Host; Itraconazole; Lipopeptides; Mycoses; Neutropenia; Opportunistic Infections; Peptides, Cyclic; Pyrimidines; Triazoles; Voriconazole | 2005 |
[Fungal peritonitis episodes in a peritoneal dialysis centre during a 10-year period: a report of 11 cases].
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antifungal Agents; Candidiasis; Caspofungin; Echinocandins; Female; Fluconazole; Flucytosine; Humans; Injections, Intraperitoneal; Injections, Intravenous; Lipopeptides; Male; Middle Aged; Peptides, Cyclic; Peritoneal Dialysis, Continuous Ambulatory; Peritonitis; Prognosis; Retrospective Studies; Risk Factors; Time Factors | 2005 |
Oral epithelial cell antifungal activity: approaches to evaluate a broad range of clinical conditions.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Candida; Candidiasis, Oral; Caspofungin; Echinocandins; Epithelial Cells; Fixatives; Fluconazole; HIV; HIV Infections; Humans; Lipopeptides; Mouth Mucosa; Peptides, Cyclic; Smoking | 2005 |
Empirical anti-Candida therapy among selected patients in the intensive care unit: a cost-effectiveness analysis.
Topics: Amphotericin B; Anti-Bacterial Agents; Antifungal Agents; Candidiasis; Caspofungin; Cost-Benefit Analysis; Cross Infection; Decision Support Techniques; Echinocandins; Fluconazole; Humans; Intensive Care Units; Lipopeptides; Microbiological Techniques; Peptides, Cyclic; Prevalence; Risk Factors; Sensitivity and Specificity; Treatment Outcome | 2005 |
Successful treatment of fungus balls due to fluconazole-resistant Candida sake obstructing ureter stents in a renal transplant patient.
Topics: Aged; Amphotericin B; Antifungal Agents; Candida; Candidiasis; Caspofungin; Device Removal; Drug Therapy, Combination; Echinocandins; Fluconazole; Humans; Kidney Transplantation; Lipopeptides; Male; Microbial Sensitivity Tests; Peptides, Cyclic; Reoperation; Stents; Therapeutic Irrigation; Treatment Outcome; Urography | 2006 |
Combination of caspofungin and an azole or an amphotericin B formulation in invasive fungal infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amphotericin B; Antifungal Agents; Caspofungin; Child, Preschool; Drug Therapy, Combination; Echinocandins; Fluconazole; Humans; Lipopeptides; Middle Aged; Mycoses; Peptides, Cyclic; Risk Factors | 2006 |
Combination therapy of disseminated coccidioidomycosis with caspofungin and fluconazole.
Topics: Adult; Antifungal Agents; Caspofungin; Coccidioidomycosis; Drug Therapy, Combination; Echinocandins; Fluconazole; Humans; Korea; Lipopeptides; Lung Diseases, Fungal; Male; Peptides, Cyclic; Pneumonia | 2006 |
Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.
Topics: Amphotericin B; Antifungal Agents; Caspofungin; Echinocandins; Fluconazole; Flucytosine; Fungi; Humans; Itraconazole; Lipopeptides; Microbial Sensitivity Tests; Mycoses; Peptides, Cyclic; Pyrimidines; Spain; Triazoles; Voriconazole; Yeasts | 2006 |
Susceptibility of Cryptococcus neoformans biofilms to antifungal agents in vitro.
Topics: Amphotericin B; Antifungal Agents; Biofilms; Biomass; Caspofungin; Cryptococcus neoformans; Dose-Response Relationship, Drug; Echinocandins; Enzyme-Linked Immunosorbent Assay; Fluconazole; Formazans; Lipopeptides; Melanins; Microbial Sensitivity Tests; Microscopy, Confocal; Peptides, Cyclic; Plankton; Pyrimidines; Triazoles; Voriconazole | 2006 |
Trichosporon asahii fungemia in a patient with non-hematological malignancy.
Topics: Aged; Antifungal Agents; Carcinoma, Transitional Cell; Caspofungin; Cystectomy; Drug Resistance, Multiple, Fungal; Echinocandins; Fatal Outcome; Female; Fluconazole; Fungemia; Humans; Lipopeptides; Microbial Sensitivity Tests; Peptides, Cyclic; Trichosporon; Urinary Bladder Neoplasms | 2006 |
Caspofungin in the treatment of azole-refractory esophageal candidiasis in kidney transplant recipients.
Topics: Adult; Aged; Antifungal Agents; Candidiasis; Candidiasis, Vulvovaginal; Caspofungin; Cyclosporine; Echinocandins; Esophageal Diseases; Female; Fluconazole; Follow-Up Studies; Graft Rejection; Humans; Immunosuppressive Agents; Incidence; Kidney Transplantation; Lipopeptides; Middle Aged; Peptides, Cyclic; Postoperative Complications; Retrospective Studies; Tacrolimus; Time Factors | 2006 |
Successful treatment of Candida tropicalis arthritis, osteomyelitis and costochondritis with caspofungin and fluconazole in a recipient of bone marrow transplantation.
Topics: Adolescent; Antifungal Agents; Arthritis, Infectious; Bone Marrow Transplantation; Candida tropicalis; Candidiasis; Caspofungin; Echinocandins; Fluconazole; Humans; Lipopeptides; Male; Osteomyelitis; Peptides, Cyclic; Tietze's Syndrome | 2006 |
Successful treatment of Candida parapsilosis (fluconazole-resistant) osteomyelitis with caspofungin in a HIV patient.
Topics: Candida; Candidiasis; Caspofungin; Drug Resistance, Microbial; Echinocandins; Fluconazole; HIV; HIV Infections; Humans; Lipopeptides; Male; Middle Aged; Osteomyelitis; Peptides, Cyclic | 2006 |
Epidemiology and outcome of Rhodotorula fungemia in a tertiary care hospital.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Agents; Caspofungin; Catheterization, Central Venous; Child; Drug Resistance, Fungal; Echinocandins; Female; Fluconazole; Fungemia; Hospitals; Humans; Lipopeptides; Male; Middle Aged; Neoplasms; Peptides, Cyclic; Retrospective Studies; Rhodotorula; Risk Factors; Treatment Outcome | 2006 |
Severe Candida albicans panophthalmitis treated with all available and potentially effective antifungal drugs: fluconazole, liposomal amphotericin B, caspofungin, and voriconazole.
Topics: Amphotericin B; Antifungal Agents; Candida albicans; Candidiasis; Caspofungin; Echinocandins; Fluconazole; Humans; Lipopeptides; Male; Middle Aged; Panophthalmitis; Peptides, Cyclic; Pyrimidines; Triazoles; Voriconazole | 2006 |
Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program.
Topics: Candida; Candidiasis; Caspofungin; Drug Resistance, Fungal; Echinocandins; Fluconazole; Global Health; Humans; Lipopeptides; Peptides, Cyclic; Population Surveillance; Pyrimidines; Triazoles; Voriconazole | 2006 |
Successful treatment of azole-resistant chronic mucocutaneous candidosis with caspofungin.
Topics: Adolescent; Antifungal Agents; Candidiasis, Chronic Mucocutaneous; Caspofungin; Drug Resistance, Fungal; Echinocandins; Female; Fluconazole; Humans; Itraconazole; Lipopeptides; Peptides, Cyclic | 2006 |
Correlation of Neo-Sensitabs tablet diffusion assay results on three different agar media with CLSI broth microdilution M27-A2 and disk diffusion M44-A results for testing susceptibilities of Candida spp. and Cryptococcus neoformans to amphotericin B, cas
Topics: Amphotericin B; Antifungal Agents; Candida; Caspofungin; Cryptococcus neoformans; Echinocandins; Fluconazole; Humans; Itraconazole; Lipopeptides; Microbial Sensitivity Tests; Peptides, Cyclic; Pyrimidines; Reagent Kits, Diagnostic; Reproducibility of Results; Triazoles; Voriconazole | 2007 |
Induction of a high affinity fibronectin receptor in Candida albicans by caspofungin: requirements for beta (1,6) glucans and the developmental regulator Hbr1p.
Topics: Aminoglycosides; Antifungal Agents; beta-Glucans; Candida albicans; Caspofungin; Echinocandins; Fluconazole; Fungal Proteins; Genetic Complementation Test; Glucan Endo-1,3-beta-D-Glucosidase; Integrin alpha5beta1; Lipopeptides; Macromolecular Substances; Mutation; Peptide Hydrolases; Peptides, Cyclic | 2007 |
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.
Topics: Amphotericin B; Antifungal Agents; Caspofungin; Echinocandins; Fluconazole; Flucytosine; Humans; In Vitro Techniques; Itraconazole; Ketoconazole; Lipopeptides; Microbial Sensitivity Tests; Mucormycosis; Peptides, Cyclic; Pyrimidines; Triazoles; Voriconazole | 2007 |
Acquired resistance to echinocandins in Candida albicans: case report and review.
Topics: Adult; Amino Acid Sequence; Amino Acid Substitution; Amphotericin B; Antifungal Agents; Candida albicans; Candidiasis; Caspofungin; Drug Resistance, Fungal; Echinocandins; Fluconazole; Genotype; HIV Infections; HIV-1; Humans; Lipopeptides; Lipoproteins; Male; Micafungin; Microbial Sensitivity Tests; Molecular Sequence Data; Peptides, Cyclic; Pyrimidines; Treatment Failure; Triazoles; Voriconazole | 2007 |
In vitro activity of fluconazole, voriconazole and caspofungin against clinical yeast isolates.
Topics: Antifungal Agents; Candida; Caspofungin; Drug Resistance, Fungal; Echinocandins; Fluconazole; Humans; Lipopeptides; Microbial Sensitivity Tests; Peptides, Cyclic; Pyrimidines; Triazoles; Voriconazole | 2007 |
Persistence of Candida albicans candidemia in non-neutropenic surgical patients: management of a representative patient in the absence of second-line treatment guidelines.
Topics: Amphotericin B; Antifungal Agents; Candida albicans; Caspofungin; Drug Combinations; Echinocandins; Female; Fluconazole; Fungemia; Humans; Ileostomy; Lipopeptides; Middle Aged; Peptides, Cyclic; Phosphatidylcholines; Phosphatidylglycerols; Postoperative Complications; Practice Guidelines as Topic | 2007 |
[Biofilm production and antifungal susceptibility patterns of Candida species isolated from hospitalized patients].
Topics: Amphotericin B; Antifungal Agents; Biofilms; Candida; Candidiasis; Caspofungin; Drug Resistance, Fungal; Echinocandins; Fluconazole; Fungemia; Humans; Itraconazole; Lipopeptides; Microbial Sensitivity Tests | 2007 |
Candidemia-induced acute interstitial nephritis.
Topics: Acute Disease; Administration, Oral; Adult; Antifungal Agents; Candidiasis; Caspofungin; Diagnosis, Differential; Echinocandins; Female; Fluconazole; Gallium Radioisotopes; Humans; Injections, Intravenous; Lipopeptides; Nephritis, Interstitial; Radionuclide Imaging | 2007 |
Activity of caspofungin and voriconazole against clinical isolates of Candida and other medically important yeasts by the CLSI M-44A disk diffusion method with Neo-Sensitabs tablets.
Topics: Amphotericin B; Antifungal Agents; Candida; Caspofungin; Cryptococcus; Disk Diffusion Antimicrobial Tests; Drug Resistance, Fungal; Echinocandins; Fluconazole; Itraconazole; Ketoconazole; Lipopeptides; Pyrimidines; Rhodotorula; Triazoles; Trichosporon; Voriconazole | 2008 |
Increasing incidence of Candida parapsilosis candidemia with caspofungin usage.
Topics: Academic Medical Centers; Antifungal Agents; Candida; Candidiasis; Caspofungin; Drug Resistance, Fungal; Echinocandins; Fluconazole; Fungemia; Humans; Incidence; Lipopeptides; Maryland; Microbial Sensitivity Tests; Regression Analysis | 2008 |
Mechanism-based pharmacokinetic-pharmacodynamic models of in vitro fungistatic and fungicidal effects against Candida albicans.
Topics: Antifungal Agents; Candida albicans; Candidiasis; Caspofungin; Colony Count, Microbial; Dose-Response Relationship, Drug; Drug Resistance, Fungal; Echinocandins; Fluconazole; Humans; Lipopeptides; Microbial Sensitivity Tests; Models, Biological | 2008 |
Candida dubliniensis meningitis as delayed sequela of treated C. dubliniensis fungemia.
Topics: Antifungal Agents; Candida; Candidiasis; Caspofungin; Echinocandins; Fluconazole; Fungemia; Heart Transplantation; Humans; Lipopeptides; Male; Meningitis, Fungal; Middle Aged | 2008 |
Breakthrough C. parapsilosis and C. guilliermondii blood stream infections in allogeneic hematopoietic stem cell transplant recipients receiving long-term caspofungin therapy.
Topics: Adolescent; Adult; Anemia, Aplastic; Antifungal Agents; Candida; Candidiasis; Caspofungin; Echinocandins; Fluconazole; Fungemia; Hematopoietic Stem Cell Transplantation; Humans; Lipopeptides; Lymphoma, Non-Hodgkin; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Premedication; Retrospective Studies; Transplantation, Homologous; Treatment Failure | 2008 |
In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.
Topics: Anidulafungin; Antifungal Agents; Candida; Candida glabrata; Caspofungin; Echinocandins; Fluconazole; Lipopeptides; Micafungin; Microbial Sensitivity Tests; Pyrimidines; Triazoles; Voriconazole | 2008 |
Significant differences in drug susceptibility among species in the Candida parapsilosis group.
Topics: Anidulafungin; Antifungal Agents; Candida; Candidiasis; Caspofungin; Echinocandins; Fluconazole; Humans; Lipopeptides; Microbial Sensitivity Tests; Random Amplified Polymorphic DNA Technique | 2008 |
Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) surveillance study.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Amphotericin B; Antifungal Agents; Candida; Candida albicans; Candida glabrata; Candida tropicalis; Candidiasis; Caspofungin; Child; Child, Preschool; Echinocandins; Female; Fluconazole; Humans; Infant; Infant, Newborn; Itraconazole; Lipopeptides; Male; Mexico; Microbial Sensitivity Tests; Middle Aged; Pyrimidines; Thiazoles; Triazoles; Voriconazole; Young Adult | 2008 |
Double-blind active-control trials: beware the comparator you keep.
Topics: Amphotericin B; Antifungal Agents; Candidiasis; Caspofungin; Double-Blind Method; Echinocandins; Fever; Fluconazole; HIV Infections; Humans; Lipopeptides; Randomized Controlled Trials as Topic | 2008 |
Dynamic, morphotype-specific Candida albicans beta-glucan exposure during infection and drug treatment.
Topics: Animals; Antifungal Agents; beta-Glucans; Candida albicans; Candidiasis; Caspofungin; Cell Wall; Disease Models, Animal; Echinocandins; Epitopes; Female; Fluconazole; Host-Pathogen Interactions; Hyphae; Lectins, C-Type; Lipopeptides; Membrane Proteins; Mice; Mice, Inbred BALB C; Microscopy, Fluorescence; Mutation; Nerve Tissue Proteins; Receptors, Immunologic | 2008 |
Alternaria keratitis: clinical presentation and resolution with topical fluconazole or intrastromal voriconazole and topical caspofungin.
Topics: Administration, Topical; Adult; Aged; Alternaria; Antifungal Agents; Caspofungin; Cataract Extraction; Contact Lenses; Corneal Stroma; Drug Therapy, Combination; Echinocandins; Eye Infections, Fungal; Eye Injuries; Female; Fluconazole; Humans; Injections; Keratitis; Lipopeptides; Male; Medical Records; Middle Aged; Pyrimidines; Steroids; Treatment Outcome; Triazoles; Voriconazole | 2009 |
Seven-year trend analysis of nosocomial candidemia and antifungal (fluconazole and caspofungin) use in Intensive Care Units at a Brazilian University Hospital.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Brazil; Candidiasis; Caspofungin; Child; Cross Infection; Echinocandins; Female; Fluconazole; Hospitals, University; Humans; Incidence; Intensive Care Units; Lipopeptides; Male; Middle Aged; Young Adult | 2008 |
Is Candida colonization of central vascular catheters in non-candidemic, non-neutropenic patients an indication for antifungals?
Topics: Antifungal Agents; Candida albicans; Candidiasis; Caspofungin; Catheterization, Central Venous; Catheters, Indwelling; Disease Progression; Echinocandins; Female; Fluconazole; Humans; Lipopeptides; Male; Middle Aged; Retrospective Studies; Statistics, Nonparametric | 2009 |
In vitro analyses of the combination of high-dose doxycycline and antifungal agents against Candida albicans biofilms.
Topics: Amphotericin B; Antifungal Agents; Biofilms; Candida albicans; Caspofungin; Dose-Response Relationship, Drug; Doxycycline; Drug Interactions; Drug Therapy, Combination; Echinocandins; Fluconazole; Humans; Lipopeptides; Microbial Sensitivity Tests | 2009 |
In vitro synergistic effects of antituberculous drugs plus antifungals against Coccidioides posadasii.
Topics: Amphotericin B; Antifungal Agents; Antitubercular Agents; Caspofungin; Coccidioides; Coccidioidomycosis; Drug Synergism; Echinocandins; Ethambutol; Fluconazole; Humans; Isoniazid; Itraconazole; Ketoconazole; Lipopeptides; Microbial Sensitivity Tests; Pyrazinamide; Pyrimidines; Triazoles; Voriconazole | 2009 |
[Candida albicans endocarditis after pulmonary artery banding].
Topics: Administration, Oral; Aneurysm, False; Aneurysm, Infected; Antifungal Agents; Candidiasis; Caspofungin; Echinocandins; Echocardiography; Endocarditis; Fluconazole; Foreign-Body Migration; Heart Septal Defects, Ventricular; Humans; Infant; Infusions, Intravenous; Lipopeptides; Male; Postoperative Care; Postoperative Complications; Pulmonary Artery; Reoperation; Thrombectomy | 2009 |
Breakthrough rhinocerebral mucormycosis in a liver transplant patient receiving caspofungin.
Topics: Adult; Antifungal Agents; Caspofungin; Echinocandins; Fatal Outcome; Female; Fluconazole; Hepatitis; Humans; Immunosuppressive Agents; Kidney Transplantation; Lipopeptides; Liver Transplantation; Mucormycosis; Rhizopus | 2009 |
Comparison of antifungal MICs for yeasts obtained using the EUCAST method in a reference laboratory and the Etest in nine different hospital laboratories.
Topics: Amphotericin B; Antifungal Agents; Candida; Caspofungin; Cryptococcus neoformans; Drug Resistance, Fungal; Echinocandins; Fluconazole; Flucytosine; Fungemia; Itraconazole; Laboratories, Hospital; Lipopeptides; Microbial Sensitivity Tests; Pyrimidines; Reference Values; Triazoles; Voriconazole; Yeasts | 2010 |
Assessment of the in vitro kinetic activity of caspofungin against Candida glabrata.
Topics: Amphotericin B; Antifungal Agents; Azoles; Candida glabrata; Caspofungin; Drug Combinations; Drug Resistance, Fungal; Drug Synergism; Echinocandins; Fluconazole; Kinetics; Lipopeptides; Microbial Sensitivity Tests; Pyrimidines; Time Factors; Triazoles; Voriconazole | 2010 |
Intraventricular fungus ball: a unique manifestation of refractory intracranial candidiasis in an immunocompetent neonate.
Topics: Administration, Oral; Amphotericin B; Antifungal Agents; Brain Diseases; Candidiasis; Caspofungin; Echinocandins; Endoscopy; Ependyma; Female; Fluconazole; Humans; Immunocompetence; Infant, Newborn; Injections, Spinal; Lipopeptides; Magnetic Resonance Imaging; Postoperative Care; Recurrence; Reoperation; Ventriculoperitoneal Shunt | 2009 |
In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp.
Topics: Amphotericin B; Anidulafungin; Antifungal Agents; Ascomycota; Caspofungin; Chromoblastomycosis; Drug Resistance, Fungal; Echinocandins; Fluconazole; Humans; In Vitro Techniques; Itraconazole; Lipopeptides; Microbial Sensitivity Tests; Nitriles; Pyridines; Pyrimidines; Triazoles; Voriconazole | 2010 |
The impact of delaying the initiation of appropriate antifungal treatment for Candida bloodstream infection.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antifungal Agents; APACHE; Candida; Candidiasis; Caspofungin; Drug Administration Schedule; Echinocandins; Female; Fluconazole; Fungemia; Humans; Lipopeptides; Male; Middle Aged; Retrospective Studies; Statistics, Nonparametric; Treatment Outcome | 2010 |
Synergistic activities of three triazoles with caspofungin against Candida glabrata isolates determined by time-kill, Etest, and disk diffusion methods.
Topics: Antifungal Agents; Candida glabrata; Caspofungin; Disk Diffusion Antimicrobial Tests; Drug Resistance, Fungal; Drug Synergism; Echinocandins; Endpoint Determination; Fluconazole; Itraconazole; Lipopeptides; Pyrimidines; Time Factors; Triazoles; Voriconazole | 2010 |
Interaction of Candida albicans biofilms with antifungals: transcriptional response and binding of antifungals to beta-glucans.
Topics: Amphotericin B; Antifungal Agents; beta-Glucans; Biofilms; Candida albicans; Caspofungin; Drug Resistance, Fungal; Echinocandins; Extracellular Matrix Proteins; Fluconazole; Fungal Proteins; Gene Expression Profiling; Gene Expression Regulation, Fungal; Lipopeptides; Luciferases; Membrane Glycoproteins; Transcription, Genetic | 2010 |
Liposomal amphotericin B eradicates Candida albicans biofilm in a continuous catheter flow model.
Topics: Amphotericin B; Antifungal Agents; Biofilms; Candida albicans; Caspofungin; Catheter-Related Infections; Catheters, Indwelling; Echinocandins; Extracellular Matrix; Fluconazole; Lipopeptides; Microbial Viability; Microscopy, Confocal; Microscopy, Electron, Scanning; Time Factors | 2010 |
Efficacy of anidulafungin, caspofungin and fluconazole in the early phase of infection in a neutropenic murine invasive candidiasis model.
Topics: Anidulafungin; Animals; Antifungal Agents; Candida albicans; Candidiasis; Caspofungin; Colony Count, Microbial; Disease Models, Animal; Echinocandins; Female; Fluconazole; Humans; Immunocompromised Host; Kidney; Lipopeptides; Mice; Mice, Inbred ICR; Neutropenia; Spleen; Treatment Outcome | 2010 |
Generation of mutants in Candida albicans with reduced susceptibility to caspofungin: influence on other antifungal products.
Topics: Amphotericin B; Antifungal Agents; Candida albicans; Caspofungin; Drug Resistance, Fungal; Echinocandins; Fluconazole; Itraconazole; Lipopeptides; Microbial Sensitivity Tests; Mutation; Pyrimidines; Triazoles; Voriconazole | 2010 |
In vitro activity of the lipopeptide PAL-Lys-Lys-NH2, alone and in combination with antifungal agents, against clinical isolates of Candida spp.
Topics: Amphotericin B; Antifungal Agents; Candida; Caspofungin; Echinocandins; Fluconazole; Lipopeptides; Lipoproteins; Microbial Sensitivity Tests | 2011 |
Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients.
Topics: Adult; Antifungal Agents; Candida; Candida albicans; Candidemia; Caspofungin; Child; Child, Preschool; Cross Infection; Drug Resistance, Fungal; Echinocandins; Fluconazole; France; Humans; Lipopeptides; Microbial Sensitivity Tests; Paris; Population Surveillance; Prevalence; Prospective Studies; Species Specificity | 2011 |
In vitro evaluation of antibiotic lock technique for the treatment of Candida albicans, C. glabrata, and C. tropicalis biofilms.
Topics: Amphotericin B; Antifungal Agents; Biofilms; Candida albicans; Candida glabrata; Candida tropicalis; Candidiasis; Caspofungin; Catheter-Related Infections; Catheterization, Central Venous; Drug Administration Routes; Echinocandins; Fluconazole; Humans; Itraconazole; Lipopeptides; Microbial Sensitivity Tests; Pyrimidines; Triazoles; Voriconazole | 2010 |
Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study.
Topics: Aged; Antifungal Agents; Candida albicans; Candidiasis; Caspofungin; Cross Infection; Echinocandins; Female; Fluconazole; Humans; Intensive Care Units; Lipopeptides; Male; Middle Aged; Prevalence; Retrospective Studies; Sepsis | 2011 |
Antifungal susceptibility of bloodstream Candida isolates in Sfax hospital: Tunisia.
Topics: Adult; Amphotericin B; Antifungal Agents; Candida; Candidemia; Caspofungin; Drug Resistance, Fungal; Echinocandins; Female; Fluconazole; Humans; Lipopeptides; Male; Microbial Sensitivity Tests; Pyrimidines; Retrospective Studies; Triazoles; Tunisia; Voriconazole | 2011 |
Catheter-related candidemia caused by Candida haemulonii in a patient in long-term hospital care.
Topics: Aged; Amphotericin B; Antifungal Agents; Candida; Candidiasis; Caspofungin; Catheter-Related Infections; Echinocandins; Fluconazole; Hospitals; Humans; Lipopeptides; Long-Term Care; Male; Phylogeny | 2011 |
Conservative management of Candida infection of prosthetic aortic graft by means of caspofungin and fluconazole alone.
Topics: Antifungal Agents; Aorta, Thoracic; Aortography; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Candidiasis; Caspofungin; Drug Administration Schedule; Drug Therapy, Combination; Echinocandins; Echocardiography, Transesophageal; Embolism; Fluconazole; Humans; Lipopeptides; Magnetic Resonance Angiography; Male; Middle Aged; Positron-Emission Tomography; Prosthesis Design; Prosthesis-Related Infections; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Effects of fluconazole, amphotericin B, and caspofungin on Candida albicans biofilms under conditions of flow and on biofilm dispersion.
Topics: Amphotericin B; Antifungal Agents; Biofilms; Candida albicans; Caspofungin; Echinocandins; Fluconazole; Lipopeptides; Microbial Sensitivity Tests | 2011 |
Calcineurin controls drug tolerance, hyphal growth, and virulence in Candida dubliniensis.
Topics: Animals; Antifungal Agents; Biofilms; Calcineurin; Candida; Candidemia; Candidiasis, Oral; Caspofungin; Colony Count, Microbial; Dentures; Drug Resistance, Fungal; Echinocandins; Eye Infections, Fungal; Fluconazole; Gene Knockdown Techniques; Humans; Hyphae; Lipopeptides; Male; Mice; Mice, Inbred ICR; Microbial Viability; Moths; Rats; Rats, Sprague-Dawley; Virulence | 2011 |
Addition of DNase improves the in vitro activity of antifungal drugs against Candida albicans biofilms.
Topics: Amphotericin B; Antifungal Agents; Biofilms; Candida albicans; Caspofungin; Deoxyribonucleases; Drug Combinations; Echinocandins; Fluconazole; Lipopeptides; Microbial Sensitivity Tests; Mitochondria; Reproducibility of Results; Tetrazolium Salts | 2012 |
In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Candida spp. as determined by CLSI broth microdilution method.
Topics: Antifungal Agents; Candida; Caspofungin; Culture Media; Dose-Response Relationship, Drug; Drug Resistance, Fungal; Echinocandins; Fluconazole; Lipopeptides; Microbial Sensitivity Tests; Pyrimidines; Triazoles; Voriconazole | 2011 |
Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes.
Topics: Aged; Antifungal Agents; APACHE; Candida; Candidemia; Caspofungin; Drug Utilization; Echinocandins; Female; Fluconazole; Humans; Intensive Care Units; Length of Stay; Lipopeptides; Male; Microbial Sensitivity Tests; Middle Aged; Retrospective Studies; Risk Factors | 2011 |
Use of antifungal agents in pediatric and adult high-risk areas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amphotericin B; Antifungal Agents; Aspergillosis; Aspergillus; Candida; Candidiasis; Caspofungin; Child; Child, Preschool; Drug Utilization; Echinocandins; Female; Fluconazole; Humans; Immunocompromised Host; Inappropriate Prescribing; Infant; Intensive Care Units; Lipopeptides; Male; Middle Aged; Mycoses; Prospective Studies; Transplantation; Young Adult | 2012 |
Antifungal susceptibility and virulence attributes of bloodstream isolates of Candida from Hong Kong and Finland.
Topics: Amphotericin B; Antifungal Agents; Candida; Candidemia; Caspofungin; Drug Resistance, Fungal; Echinocandins; Finland; Fluconazole; Flucytosine; Hemolysin Proteins; Hong Kong; Humans; Itraconazole; Ketoconazole; Lipopeptides; Microbial Sensitivity Tests; Peptide Hydrolases; Pyrimidines; Triazoles; Virulence Factors; Voriconazole | 2011 |
Selection of resistant fungi in liver transplant recipients during use of newer antifungal agents -- a report of two cases.
Topics: Adult; Antifungal Agents; Caspofungin; Drug Resistance, Fungal; Echinocandins; Fatal Outcome; Female; Fluconazole; Humans; Lipopeptides; Liver Transplantation; Male; Middle Aged; Mycoses; Pyrimidines; Triazoles; Trichosporonosis; Voriconazole; Young Adult | 2011 |
Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy.
Topics: Aged; Amphotericin B; Antifungal Agents; Candidiasis; Caspofungin; Communicable Disease Control; Cross Infection; Echinocandins; Female; Fluconazole; Hospitals; Humans; Italy; Itraconazole; Lipopeptides; Male; Middle Aged; Pyrimidines; Treatment Outcome; Triazoles; Voriconazole | 2011 |
Fungicidal activity of the human peptide hepcidin 20 alone or in combination with other antifungals against Candida glabrata isolates.
Topics: Acids; Amphotericin B; Antifungal Agents; Antimicrobial Cationic Peptides; Candida glabrata; Caspofungin; Drug Synergism; Echinocandins; Fluconazole; Hepcidins; Humans; Hydrogen-Ion Concentration; Lipopeptides; Microbial Sensitivity Tests; Peptide Fragments | 2011 |
[Trends in systemic antifungal use in critically ill patients. Multicenter observational study, 2006-2010].
Topics: Amphotericin B; Antifungal Agents; Caspofungin; Community-Acquired Infections; Critical Illness; Cross Infection; Drug Prescriptions; Drug Utilization; Echinocandins; Female; Fluconazole; Hospital Bed Capacity; Humans; Immunocompromised Host; Intensive Care Units; Lipopeptides; Male; Middle Aged; Mycoses; Neutropenia; Prospective Studies; Registries; Spain | 2012 |
[Study on in vitro susceptibility of Candida spp. isolated from blood culture].
Topics: Amphotericin B; Antifungal Agents; Blood; Candida; Candidiasis; Caspofungin; Drug Resistance, Fungal; Echinocandins; Fluconazole; Flucytosine; Hospitals; Humans; In Vitro Techniques; Itraconazole; Lipopeptides; Microbial Sensitivity Tests; Pyrimidines; Reproducibility of Results; Risk Factors; Triazoles; Voriconazole | 2012 |
Nonspecific effect of Mycograb on amphotericin B MIC.
Topics: Amphotericin B; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antifungal Agents; Candida albicans; Caspofungin; Drug Interactions; Echinocandins; Fluconazole; Humans; Lipopeptides; Microbial Sensitivity Tests | 2012 |
The activity of echinocandins, amphotericin B and voriconazole against fluconazole-susceptible and fluconazole-resistant Brazilian Candida glabrata isolates.
Topics: Amphotericin B; Anidulafungin; Antifungal Agents; Candida glabrata; Caspofungin; Drug Resistance, Fungal; Echinocandins; Fluconazole; Humans; Lipopeptides; Micafungin; Microbial Sensitivity Tests; Pyrimidines; Triazoles; Voriconazole | 2012 |
Comparison of the kidney fungal burden in experimental disseminated candidiasis by species of the Candida parapsilosis complex treated with fluconazole, amphotericin B and caspofungin in a temporarily neutropenic murine model.
Topics: Amphotericin B; Animals; Antifungal Agents; Candida; Caspofungin; Disease Models, Animal; Echinocandins; Female; Fluconazole; Immunocompromised Host; Kidney; Lipopeptides; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Neutropenia | 2012 |
Fluconazole exposure rather than clonal spreading is correlated with the emergence of Candida glabrata with cross-resistance to triazole antifungal agents.
Topics: Amphotericin B; Antifungal Agents; Candida glabrata; Caspofungin; Drug Resistance, Fungal; Echinocandins; Fluconazole; Itraconazole; Ketoconazole; Lipopeptides; Microbial Sensitivity Tests; Pyrimidines; Triazoles; Voriconazole | 2012 |
Histoplasmosis in HIV-positive patients in Ceará, Brazil: clinical-laboratory aspects and in vitro antifungal susceptibility of Histoplasma capsulatum isolates.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Brazil; Caspofungin; CD4 Lymphocyte Count; Echinocandins; Female; Fluconazole; Histoplasma; Histoplasmosis; Humans; Itraconazole; L-Lactate Dehydrogenase; Lipopeptides; Male; Microbial Sensitivity Tests; Pyrimidines; Triazoles; Voriconazole | 2012 |
Minimum inhibitory concentrations of amphotericin B, azoles and caspofungin against Candida species are reduced by farnesol.
Topics: Amphotericin B; Animals; Antifungal Agents; Candida; Candidiasis; Caspofungin; Drug Resistance, Fungal; Drug Synergism; Echinocandins; Farnesol; Fluconazole; Humans; Itraconazole; Lipopeptides; Microbial Sensitivity Tests | 2013 |
In vitro activities of nine antifungal drugs against 81 Phialophora and Cyphellophora isolates.
Topics: Amphotericin B; Antifungal Agents; Caspofungin; Echinocandins; Fluconazole; Itraconazole; Lipopeptides; Micafungin; Microbial Sensitivity Tests; Mitosporic Fungi; Naphthalenes; Nitriles; Phialophora; Pyridines; Pyrimidines; Terbinafine; Triazoles; Voriconazole | 2012 |
Prevalence and antifungal susceptibility of Candida parapsilosis complex isolates collected from oral cavities of HIV-infected individuals.
Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis, Oral; Caspofungin; Echinocandins; Female; Fluconazole; HIV Infections; Humans; Lipopeptides; Male; Microbial Sensitivity Tests; Mouth; Mycological Typing Techniques; Polymorphism, Restriction Fragment Length; Pyrimidines; Triazoles; Voriconazole | 2012 |
Colonization of the oral cavity by yeasts in patients with chronic renal failure undergoing hemodialysis.
Topics: Adult; Aged; Aged, 80 and over; Amphotericin B; Antifungal Agents; Candida; Candida albicans; Candida glabrata; Candida tropicalis; Caspofungin; Colony Count, Microbial; Dentures; Diabetes Complications; Echinocandins; Female; Fluconazole; Humans; Hypertension; Kidney Failure, Chronic; Lipopeptides; Male; Microbial Sensitivity Tests; Middle Aged; Mouth; Mycology; Nystatin; Phenotype; Pyrimidines; Renal Dialysis; Time Factors; Triazoles; Voriconazole | 2013 |
Sensitization of Candida albicans biofilms to various antifungal drugs by cyclosporine A.
Topics: Amphotericin B; Antifungal Agents; Biofilms; Candida albicans; Caspofungin; Cyclosporine; Drug Resistance, Multiple, Fungal; Drug Synergism; Echinocandins; Fluconazole; Lipopeptides; Microbial Sensitivity Tests; Nystatin; Pyrimidines; Triazoles; Voriconazole | 2012 |
Susceptibility to caspofungin and fluconazole and Als1/Als3 gene expression in biofilm and dispersal cells of Candida albicans.
Topics: Antifungal Agents; Biofilms; Candida albicans; Caspofungin; Echinocandins; Fluconazole; Fungal Proteins; Gene Expression; Lipopeptides; Up-Regulation | 2012 |
Aspergillus felis sp. nov., an emerging agent of invasive aspergillosis in humans, cats, and dogs.
Topics: Air Microbiology; Animals; Antifungal Agents; Aspergillosis; Aspergillus; Caspofungin; Cat Diseases; Cats; Communicable Diseases, Emerging; Dog Diseases; Dogs; Drug Resistance, Fungal; Echinocandins; Fluconazole; Genes, Fungal; Humans; Lipopeptides; Male; Microbial Sensitivity Tests; Middle Aged; Multilocus Sequence Typing; Phylogeny; Rhinitis; Sinusitis | 2013 |
Mechanism of action of novel synthetic dodecapeptides against Candida albicans.
Topics: Antifungal Agents; Apoptosis; Candida albicans; Caspofungin; Cell Membrane Permeability; Cell Wall; Drug Synergism; Echinocandins; Fluconazole; Hemolysis; Lipopeptides; Necrosis; Peptides; Reactive Oxygen Species | 2013 |
Chromosome 5 monosomy of Candida albicans controls susceptibility to various toxic agents, including major antifungals.
Topics: Amphotericin B; Antifungal Agents; Candida albicans; Caspofungin; Chromosomes, Fungal; Echinocandins; Fluconazole; Flucytosine; Lipopeptides | 2013 |
Susceptibility profile of a Brazilian yeast stock collection of Candida species isolated from subjects with Candida-associated denture stomatitis with or without diabetes.
Topics: Amphotericin B; Antifungal Agents; Brazil; Candida; Candidiasis, Oral; Caspofungin; Diabetes Mellitus; Drug Resistance, Fungal; Echinocandins; Fluconazole; Humans; Itraconazole; Lipopeptides; Microbial Sensitivity Tests; Stomatitis, Denture | 2013 |
In vitro activities of eight antifungal drugs against 106 waterborne and cutaneous exophiala species.
Topics: Amphotericin B; Antifungal Agents; Caspofungin; Echinocandins; Exophiala; Fluconazole; Itraconazole; Lipopeptides; Micafungin; Microbial Sensitivity Tests; Nitriles; Pyridines; Pyrimidines; Triazoles; Voriconazole | 2013 |
Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candidaemia s
Topics: Antifungal Agents; Candida; Candidemia; Caspofungin; Drug Resistance, Fungal; Echinocandins; Fluconazole; Lipopeptides; Microbial Sensitivity Tests; Prospective Studies; Switzerland; Voriconazole | 2014 |
In vitro study of sequential fluconazole and caspofungin treatment against Candida albicans biofilms.
Topics: Adaptation, Physiological; Antifungal Agents; Biofilms; Calcineurin; Candida albicans; Caspofungin; Echinocandins; Fluconazole; Fungal Proteins; Gene Expression Regulation, Fungal; HSP90 Heat-Shock Proteins; Lipopeptides; Microbial Sensitivity Tests; Stress, Physiological; Time Factors | 2014 |
In vitro susceptibility of Candida species to four antifungal agents assessed by the reference broth microdilution method.
Topics: Amphotericin B; Antifungal Agents; Candida; Caspofungin; Drug Resistance, Fungal; Echinocandins; Fluconazole; Humans; Lipopeptides; Microbial Sensitivity Tests; Pyrimidines; Triazoles; Turkey; Voriconazole | 2013 |
In vitro pharmacodynamics and in vivo efficacy of fluconazole, amphotericin B and caspofungin in a murine infection by Candida lusitaniae.
Topics: Amphotericin B; Animals; Antifungal Agents; Candida; Candidiasis; Caspofungin; Colony Count, Microbial; Disease Models, Animal; Echinocandins; Fluconazole; Kidney; Lipopeptides; Male; Mice; Microbial Sensitivity Tests; Treatment Outcome | 2014 |
Antibiotics sensitivity of Candida clinical and food-borne isolates.
Topics: Candida; Caspofungin; Drug Resistance, Bacterial; Echinocandins; Fluconazole; Food Microbiology; Foodborne Diseases; Humans; Lipopeptides; Nystatin; Pyrimidines; Triazoles; Voriconazole | 2013 |
Activities of fluconazole, caspofungin, anidulafungin, and amphotericin B on planktonic and biofilm Candida species determined by microcalorimetry.
Topics: Amphotericin B; Anidulafungin; Biofilms; Calorimetry; Candida; Caspofungin; Echinocandins; Fluconazole; Lipopeptides; Microbial Sensitivity Tests; Plankton | 2014 |
Evaluation of efficacy, pharmacokinetics and tolerability of peptidomimetic aspartic proteinase inhibitors as cream formulation in experimental vaginal candidiasis.
Topics: Animals; Antifungal Agents; Aspartic Acid Proteases; Candida albicans; Candidiasis; Caspofungin; Chemistry, Pharmaceutical; Echinocandins; Female; Fluconazole; Lipopeptides; Peptidomimetics; Rats; Rats, Wistar; Vaginal Creams, Foams, and Jellies; Vaginitis | 2014 |
Role of FKS Mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance.
Topics: Anidulafungin; Antifungal Agents; Candida glabrata; Candidemia; Caspofungin; Drug Resistance, Multiple, Fungal; Echinocandins; Fluconazole; Fungal Proteins; Glucosyltransferases; Lipopeptides; Micafungin; Microbial Sensitivity Tests; Mutation; United States | 2014 |
Candidemia in the intensive care unit: analysis of direct treatment costs and clinical outcome in patients treated with echinocandins or fluconazole.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anidulafungin; Antifungal Agents; Candidemia; Caspofungin; Child; Child, Preschool; Echinocandins; Female; Fluconazole; Health Care Costs; Hospitalization; Humans; Infant; Intensive Care Units; Lipopeptides; Male; Micafungin; Middle Aged; Treatment Outcome; Young Adult | 2015 |
Quinacrine inhibits Candida albicans growth and filamentation at neutral pH.
Topics: Amphotericin B; Antifungal Agents; Antiprotozoal Agents; Biofilms; Candida albicans; Caspofungin; Drug Combinations; Drug Repositioning; Drug Resistance, Fungal; Drug Synergism; Echinocandins; Endocytosis; Fluconazole; Hydrogen-Ion Concentration; Hyphae; Lipopeptides; Microbial Sensitivity Tests; Microbial Viability; Plankton; Quinacrine | 2014 |
The investigational agent E1210 is effective in treatment of experimental invasive candidiasis caused by resistant Candida albicans.
Topics: Aminopyridines; Animals; Antifungal Agents; Candida albicans; Candidiasis, Invasive; Caspofungin; Dose-Response Relationship, Drug; Drug Resistance, Fungal; Echinocandins; Fluconazole; Isoxazoles; Lipopeptides; Male; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests | 2015 |
Artemisinins, new miconazole potentiators resulting in increased activity against Candida albicans biofilms.
Topics: Amphotericin B; Antifungal Agents; Artemisinins; Artesunate; Biofilms; Candida albicans; Candidiasis; Caspofungin; Drug Synergism; Echinocandins; Fluconazole; Hexachlorophene; Lipopeptides; Miconazole; Microbial Sensitivity Tests; Pyrvinium Compounds; Reactive Oxygen Species | 2015 |
In vitro anti-yeast activity of chloramphenicol: A preliminary report.
Topics: Antifungal Agents; Candida; Caspofungin; Chloramphenicol; Cryptococcus neoformans; Echinocandins; Fluconazole; Humans; Ketoconazole; Lipopeptides; Microbial Sensitivity Tests; Pilot Projects; Saccharomyces cerevisiae | 2015 |
Caspofungin irrigation through percutaneous calicostomy catheter combined with oral flucytosine to treat fluconazole-resistant symptomatic candiduria.
Topics: Administration, Oral; Adult; Antifungal Agents; Candidiasis, Invasive; Caspofungin; Combined Modality Therapy; Drug Resistance, Fungal; Echinocandins; Fluconazole; Flucytosine; Humans; Kidney Calices; Lipopeptides; Male; Therapeutic Irrigation; Urinary Catheterization; Urinary Tract Infections | 2015 |
The development of animal infection models and antifungal efficacy assays against clinical isolates of Trichosporon asahii, T. asteroides and T. inkin.
Topics: Amphotericin B; Animals; Antifungal Agents; Caspofungin; Disease Models, Animal; Drug Resistance, Fungal; Echinocandins; Fluconazole; Immunocompromised Host; Kidney; Larva; Lipopeptides; Mice; Microbial Sensitivity Tests; Moths; Trichosporon; Trichosporonosis; Voriconazole | 2015 |
In vitro susceptibility patterns of clinically important Trichophyton and Epidermophyton species against nine antifungal drugs.
Topics: Amphotericin B; Anidulafungin; Antifungal Agents; Caspofungin; Echinocandins; Epidermophyton; Fluconazole; Humans; Itraconazole; Lipopeptides; Microbial Sensitivity Tests; Naphthalenes; Nitriles; Pyridines; Terbinafine; Tinea; Triazoles; Trichophyton; Voriconazole | 2015 |
Fungal endocarditis after hybrid periventricular closure of muscular ventricular septal defect by Amplatzer occluder in a child.
Topics: Administration, Oral; Candidiasis; Caspofungin; Child, Preschool; Echinocandins; Endocarditis; Fluconazole; Heart Septal Defects, Ventricular; Humans; Injections, Intravenous; Lipopeptides; Male; Septal Occluder Device | 2015 |
Antifungal susceptibility and phenotypic characterization of oral isolates of a black fungus from a nasopharyngeal carcinoma patient under radiotherapy.
Topics: Amphotericin B; Antifungal Agents; Biofilms; Carcinoma; Caspofungin; Chemoradiotherapy; Chemotherapy, Adjuvant; Drug Resistance, Fungal; Echinocandins; Exophiala; Fluconazole; Humans; Immunocompromised Host; Itraconazole; Ketoconazole; Lipopeptides; Male; Middle Aged; Mouth Diseases; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Opportunistic Infections; Phaeohyphomycosis; Radiotherapy, Intensity-Modulated; Voriconazole | 2015 |
Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study.
Topics: Aged; Anidulafungin; Antifungal Agents; Caspofungin; Critical Illness; Drug Monitoring; Echinocandins; Europe; Female; Fluconazole; Humans; Intensive Care Units; Lipopeptides; Male; Middle Aged | 2015 |
Protein-bound drugs are prone to sequestration in the extracorporeal membrane oxygenation circuit: results from an ex vivo study.
Topics: Caspofungin; Ceftriaxone; Echinocandins; Extracorporeal Membrane Oxygenation; Fluconazole; Humans; Lipopeptides; Models, Theoretical; Plasma; Thiopental | 2015 |
Impact of short-term exposure of antifungal agents on hemolysin activity of oral Candida dubliniensis isolates from Kuwait and Sri Lanka.
Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis, Oral; Caspofungin; Chlorhexidine; Echinocandins; Fluconazole; Hemolysin Proteins; Humans; Ketoconazole; Kuwait; Lipopeptides; Microbial Sensitivity Tests; Nystatin; Sri Lanka; Time Factors | 2016 |
In vitro activities of a wide panel of antifungal drugs against various Scopulariopsis and Microascus species.
Topics: Amphotericin B; Antifungal Agents; Ascomycota; Caspofungin; Drug Resistance, Fungal; Echinocandins; Fluconazole; Flucytosine; Itraconazole; Ketoconazole; Lipopeptides; Microbial Sensitivity Tests; Scopulariopsis; Triazoles; Voriconazole | 2015 |
Candida Surveillance in Surgical Intensive Care Unit (SICU) in a Tertiary Institution.
Topics: Adult; Aged; Aged, 80 and over; Amphotericin B; Anidulafungin; Antifungal Agents; beta-Glucans; Candida; Candida albicans; Candida glabrata; Candidiasis; Candidiasis, Invasive; Carrier State; Caspofungin; Critical Care; Echinocandins; Female; Fluconazole; Humans; Incidence; Intensive Care Units; Lipopeptides; Male; Micafungin; Microbial Sensitivity Tests; Middle Aged; Sensitivity and Specificity; Singapore; Tertiary Care Centers; Voriconazole | 2015 |
In Vitro Activities of Eight Antifungal Drugs against a Global Collection of Genotyped Exserohilum Isolates.
Topics: Amphotericin B; Amplified Fragment Length Polymorphism Analysis; Antifungal Agents; Ascomycota; Caspofungin; Echinocandins; Fluconazole; Genotype; Itraconazole; Lipopeptides; Micafungin; Microbial Sensitivity Tests; Molecular Sequence Data; Nitriles; Pyridines; Triazoles; Voriconazole | 2015 |
In Vitro Susceptibility Profiles of Eight Antifungal Drugs against Clinical and Environmental Strains of Phaeoacremonium.
Topics: Amphotericin B; Anidulafungin; Antifungal Agents; Ascomycota; Caspofungin; Echinocandins; Fluconazole; Humans; Itraconazole; Lipopeptides; Microbial Sensitivity Tests; Mycoses; Nitriles; Pyridines; Triazoles; Voriconazole | 2015 |
Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis.
Topics: Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Caspofungin; Cost-Benefit Analysis; Drug Costs; Echinocandins; Fluconazole; Humans; Intensive Care Units; Length of Stay; Lipopeptides; Micafungin; Models, Economic; Treatment Outcome; United Kingdom | 2015 |
Echinocandin Susceptibility Profile of Fluconazole Resistant Candida Species Isolated from Blood Stream Infections.
Topics: Antifungal Agents; Candida; Candida albicans; Candida glabrata; Candidemia; Candidiasis, Invasive; Caspofungin; Disease Susceptibility; Drug Resistance, Fungal; Echinocandins; Fluconazole; Humans; Lipopeptides; Microbial Sensitivity Tests | 2016 |
Can physicochemical properties of antimicrobials be used to predict their pharmacokinetics during extracorporeal membrane oxygenation? Illustrative data from ovine models.
Topics: Animals; Anti-Infective Agents; Carbapenems; Caspofungin; Ceftriaxone; Ciprofloxacin; Critical Illness; Doripenem; Echinocandins; Extracorporeal Membrane Oxygenation; Fluconazole; Gentamicins; Lipopeptides; Meropenem; Models, Theoretical; Sheep; Sheep, Domestic; Thienamycins; Vancomycin | 2015 |
Comparative effectiveness of fungicidal vs. fungistatic therapies for the treatment of paediatric candidaemia.
Topics: Adolescent; Amphotericin B; Antifungal Agents; Candidemia; Caspofungin; Child; Child, Preschool; Cohort Studies; Echinocandins; Fluconazole; Humans; Infant; Inpatients; Lipopeptides; Retrospective Studies; Treatment Outcome | 2016 |
Echinocandin to fluconazole step-down therapy in critically ill patients with invasive, susceptible Candida albicans infections.
Topics: Administration, Intravenous; Adult; Aged; Anidulafungin; Antifungal Agents; Candidiasis, Invasive; Caspofungin; Critical Illness; Echinocandins; Female; Fluconazole; Humans; Intensive Care Units; Lipopeptides; Male; Micafungin; Middle Aged; Multivariate Analysis; Retrospective Studies | 2016 |
Caspofungin versus fluconazole as prophylaxis of invasive fungal infection in high-risk liver transplantation recipients: A propensity score analysis.
Topics: Adult; Aged; Alanine Transaminase; Antifungal Agents; Aspergillosis; Bilirubin; Caspofungin; Cohort Studies; Echinocandins; Female; Fluconazole; Humans; Invasive Fungal Infections; Lipopeptides; Liver Diseases; Liver Transplantation; Male; Middle Aged; Pre-Exposure Prophylaxis; Propensity Score; Retrospective Studies; Risk; Spain; Treatment Outcome; Young Adult | 2016 |
Activation of Melanin Synthesis in Alternaria infectoria by Antifungal Drugs.
Topics: Alternaria; Aminoglycosides; Amphotericin B; Antifungal Agents; Caspofungin; Cell Wall; Echinocandins; Fluconazole; Itraconazole; Lipopeptides; Melanins; Microbial Sensitivity Tests; Naphthols; Pyrroles; Quinolines | 2015 |
In vitro activity of Caspofungin combined with Fluconazole on mixed Candida albicans and Candida glabrata biofilm.
Topics: Antifungal Agents; Biofilms; Candida albicans; Candida glabrata; Caspofungin; Drug Combinations; Echinocandins; Fluconazole; Lipopeptides; Microbial Sensitivity Tests; Microbial Viability | 2016 |
Coccidioidomycosis in infants: A retrospective case series.
Topics: Amphotericin B; Antifungal Agents; Caspofungin; Coccidioidomycosis; Cough; Diagnosis, Differential; Echinocandins; Endemic Diseases; Female; Fever; Fluconazole; Humans; Infant; Lipopeptides; Lung Diseases, Fungal; Male; Retrospective Studies; Treatment Outcome; Voriconazole | 2016 |
Antifungal therapies in murine infections by Candida kefyr.
Topics: Amphotericin B; Animals; Antifungal Agents; beta-Glucans; Candida; Candidiasis, Invasive; Caspofungin; Colony Count, Microbial; Disease Models, Animal; Echinocandins; Fluconazole; Kidney; Lipopeptides; Male; Mice; Microbial Sensitivity Tests; Microbial Viability; Proteoglycans; Survival Analysis; Treatment Outcome | 2016 |
In vitro Synergistic Activity of Caspofungin Plus Polymyxin B Against Fluconazole-Resistant Candida glabrata.
Topics: Antifungal Agents; Candida glabrata; Caspofungin; Drug Resistance, Fungal; Drug Synergism; Drug Therapy, Combination; Echinocandins; Fluconazole; Humans; Lipopeptides; Microbial Sensitivity Tests; Polymyxin B | 2016 |
Highly Dynamic and Specific Phosphatidylinositol 4,5-Bisphosphate, Septin, and Cell Wall Integrity Pathway Responses Correlate with Caspofungin Activity against Candida albicans.
Topics: Amphotericin B; Antifungal Agents; Benzenesulfonates; Candida albicans; Caspofungin; Cell Cycle Proteins; Cell Wall; Echinocandins; Fluconazole; Fungal Proteins; Green Fluorescent Proteins; Hydrogen Peroxide; Lipopeptides; Luminescent Proteins; Microbial Sensitivity Tests; Mitogen-Activated Protein Kinases; Phosphatidylinositol 4,5-Diphosphate; Phosphorylation; Protein Domains; Protein Kinase C; Red Fluorescent Protein; Septins | 2016 |
Lipid Flippase Subunit Cdc50 Mediates Drug Resistance and Virulence in Cryptococcus neoformans.
Topics: Animals; Antifungal Agents; Caspofungin; Cell Membrane; Cryptococcosis; Cryptococcus neoformans; Disease Models, Animal; Drug Resistance, Fungal; Echinocandins; Fluconazole; Fungal Proteins; Gene Deletion; Humans; Lipopeptides; Mice; Mutation; Phosphatidylserines; Phospholipid Transfer Proteins; Virulence | 2016 |
Identification and antifungal susceptibility of Candida species isolated from bloodstream infections in Konya, Turkey.
Topics: Amphotericin B; Anidulafungin; Antifungal Agents; Candida; Candida albicans; Candidiasis; Caspofungin; Echinocandins; Fluconazole; Humans; Lipopeptides; Microbial Sensitivity Tests; Species Specificity; Triazoles; Voriconazole | 2016 |
First report of monomicrobial Candida parapsilosis necrotizing fasciitis.
Topics: Amputation, Surgical; Antifungal Agents; Candida; Candidiasis, Cutaneous; Caspofungin; Echinocandins; Fasciitis, Necrotizing; Fluconazole; Humans; Hypertension, Renal; Immunocompromised Host; Immunosuppression Therapy; Kidney Transplantation; Leg; Lipopeptides; Male; Middle Aged; Nephritis | 2016 |
First isolation of Candida wangnamkhiaoensis from the blood of immunocompromised paediatric patient.
Topics: Anidulafungin; Antifungal Agents; Candida; Candidemia; Caspofungin; Child, Preschool; DNA, Ribosomal Spacer; Echinocandins; Fluconazole; Humans; Hyphae; Immunocompromised Host; Lipopeptides; Male; Phylogeny; Polymerase Chain Reaction; Sequence Alignment; Voriconazole | 2016 |
Effect of Antifungal Treatment in a Diet-Based Murine Model of Disseminated Candidiasis Acquired via the Gastrointestinal Tract.
Topics: Animals; Antifungal Agents; Candida albicans; Candidiasis; Caspofungin; Colony Count, Microbial; Cyclophosphamide; Diet; Disease Models, Animal; Echinocandins; Fluconazole; Gastrointestinal Tract; Humans; Immunocompromised Host; Immunosuppressive Agents; Lipopeptides; Male; Mice; Mice, Inbred BALB C; Prednisolone; Survival Analysis | 2016 |
The Celecoxib Derivative AR-12 Has Broad-Spectrum Antifungal Activity In Vitro and Improves the Activity of Fluconazole in a Murine Model of Cryptococcosis.
Topics: Animals; Antifungal Agents; Candida; Caspofungin; Celecoxib; Cryptococcosis; Cryptococcus neoformans; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Resistance, Fungal; Drug Synergism; Echinocandins; Fluconazole; Gene Expression Regulation, Fungal; Lipopeptides; Male; Mice, Inbred Strains; Microbial Sensitivity Tests; Pneumocystis; Pyrazoles; Saccharomyces cerevisiae; Sulfonamides | 2016 |
Fournier Gangrene Caused by Candida albicans in an Infant After Cardiac Surgery.
Topics: Antifungal Agents; Candida albicans; Candidiasis, Cutaneous; Caspofungin; Echinocandins; Fluconazole; Fournier Gangrene; Humans; Infant, Newborn; Lipopeptides; Male; Scrotum; Thoracic Surgery; Treatment Outcome | 2017 |
Epidemiology and cost implications of candidemia, a 6-year analysis from a developing country.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Candida; Candida albicans; Candida glabrata; Candidemia; Caspofungin; Child; Child, Preschool; Cross Infection; Developing Countries; Echinocandins; Epidemiological Monitoring; Female; Fluconazole; Humans; Incidence; Infant; Infant, Newborn; Length of Stay; Lipopeptides; Male; Middle Aged; Prevalence; Retrospective Studies; Time Factors; Turkey; Young Adult | 2017 |
Comparison of susceptibility patterns using commercially available susceptibility testing methods performed on prevalent Candida spp.
Topics: Anidulafungin; Antifungal Agents; Candida; Candida albicans; Candidiasis; Candidiasis, Invasive; Caspofungin; Drug Resistance, Fungal; Echinocandins; Fluconazole; Humans; Lipopeptides; Micafungin; Microbial Sensitivity Tests; Respiratory System; Urine | 2016 |
In vitro inhibitory effects of farnesol and interactions between farnesol and antifungals against biofilms of Candida albicans resistant strains.
Topics: Amphotericin B; Antifungal Agents; Biofilms; Candida albicans; Caspofungin; Drug Interactions; Drug Resistance, Fungal; Echinocandins; Farnesol; Fluconazole; Humans; Lipopeptides; Microbial Sensitivity Tests; Microscopy, Electron, Scanning; Naphthalenes; Terbinafine | 2017 |
Candida auris candidaemia in Indian ICUs: analysis of risk factors.
Topics: Adolescent; Adult; Aged; Amphotericin B; Antifungal Agents; Candida; Candidemia; Caspofungin; Echinocandins; Female; Fluconazole; Humans; India; Intensive Care Units; Lipopeptides; Male; Microbial Sensitivity Tests; Middle Aged; Mycological Typing Techniques; Risk Factors; Young Adult | 2017 |
Changing epidemiology of candidaemia in Australia.
Topics: Anidulafungin; Antifungal Agents; Australia; Azoles; Candida; Candida glabrata; Candida tropicalis; Candidemia; Caspofungin; Drug Resistance, Fungal; Echinocandins; Female; Fluconazole; Humans; Incidence; Lipopeptides; Male; Micafungin; Microbial Sensitivity Tests; Sequence Analysis, DNA; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Triazoles; Voriconazole | 2017 |
Biofilms of Candida spp. from the ocular conjunctiva of horses with reduced azole susceptibility: a complicating factor for the treatment of keratomycosis?
Topics: Amphotericin B; Animals; Antifungal Agents; Azoles; Biofilms; Candida; Caspofungin; Conjunctiva; Echinocandins; Eye Infections, Fungal; Fluconazole; Horse Diseases; Horses; Itraconazole; Keratitis; Lipopeptides; Microbial Sensitivity Tests | 2017 |
Novel properties of Hippophae rhamnoides L. twig and leaf extracts - anti-virulence action and synergy with antifungals studied in vitro on Candida spp. model.
Topics: Antifungal Agents; Biofilms; Candida; Candida albicans; Candida glabrata; Caspofungin; Cell Adhesion; Drug Combinations; Drug Synergism; Echinocandins; Fluconazole; Hippophae; Humans; Hyphae; Lipopeptides; Microbial Sensitivity Tests; Morphogenesis; Plant Extracts; Plant Leaves; Virulence; Virulence Factors | 2017 |
Diversity, in-vitro virulence traits and antifungal susceptibility pattern of gastrointestinal yeast flora of healthy poultry, Gallus gallus domesticus.
Topics: Amphotericin B; Animals; Antifungal Agents; Biodiversity; Biofilms; Caspofungin; Chickens; Colony Count, Microbial; Drug Resistance, Fungal; Echinocandins; Fluconazole; Gastrointestinal Microbiome; Lipopeptides; Microbial Sensitivity Tests; Nepal; Poultry; Virulence; Virulence Factors; Voriconazole; Yeasts | 2017 |
Pharmacoeconomic analysis of antifungal therapy for primary treatment of invasive candidiasis caused by Candida albicans and non-albicans Candida species.
Topics: Anidulafungin; Antifungal Agents; Candida; Candida albicans; Candidemia; Candidiasis, Invasive; Caspofungin; Cost-Benefit Analysis; Echinocandins; Economics, Pharmaceutical; Fluconazole; Humans; Lipopeptides; Micafungin; Taiwan; Treatment Outcome | 2017 |
Topics: Antifungal Agents; Candida; Caspofungin; Drug Interactions; Drug Resistance, Multiple, Fungal; Echinocandins; Fluconazole; Humans; Lipopeptides; Micafungin; Microbial Sensitivity Tests; Triazoles; Voriconazole | 2017 |
Clinical manifestations of candidemia caused by uncommon Candida species and antifungal susceptibility of the isolates in a regional hospital in Taiwan, 2007-2014.
Topics: Adult; Aged; Aged, 80 and over; Antifungal Agents; Azoles; Candida; Candida glabrata; Candidemia; Caspofungin; Cross Infection; Drug Resistance, Multiple, Fungal; Echinocandins; Female; Fluconazole; Humans; Infant; Male; Microbial Sensitivity Tests; Middle Aged; Molecular Typing; Mycological Typing Techniques; Phenotype; Retrospective Studies; RNA, Ribosomal, 28S; Taiwan | 2019 |
Antifungal susceptibility testing of Candida species isolated from the immunocompromised patients admitted to ten university hospitals in Iran: comparison of colonizing and infecting isolates.
Topics: Amphotericin B; Antifungal Agents; Candida; Caspofungin; Cross-Sectional Studies; Drug Resistance, Fungal; Echinocandins; Female; Fluconazole; Hospitals, University; Humans; Immunocompromised Host; Iran; Lipopeptides; Microbial Sensitivity Tests; Triazoles; Voriconazole | 2017 |
Analysis on clinical characteristics and drug resistance of Candida parapsilosis bloodstream infections in West China Hospital, China, from 2012 to 2015.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Candida parapsilosis; Candidemia; Caspofungin; Child; Child, Preschool; China; Drug Resistance, Fungal; Female; Fluconazole; Hospitals; Humans; Infant; Infant, Newborn; Male; Microbial Sensitivity Tests; Middle Aged; Retrospective Studies; Voriconazole; Young Adult | 2018 |
Candida infanticola and Candida spencermartinsiae yeasts: Possible emerging species in cancer patients.
Topics: Adolescent; Antifungal Agents; Candida; Candidiasis; Caspofungin; Child, Preschool; Echinocandins; Fluconazole; Humans; Kluyveromyces; Lipopeptides; Male; Microbial Sensitivity Tests; Middle Aged; Neoplasms; Nitriles; Opportunistic Infections; Pichia; Pyridines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Triazoles; Voriconazole | 2018 |
Three cases of Candida fermentati fungemia following hematopoietic stem cell transplantation.
Topics: Aged; Amphotericin B; Antifungal Agents; Candida; Candidemia; Caspofungin; DNA, Ribosomal; Echinocandins; Fatal Outcome; Female; Fluconazole; Hematopoietic Stem Cell Transplantation; Humans; Lipopeptides; Lymphoproliferative Disorders; Male; Middle Aged; Sequence Analysis, DNA | 2018 |
Antifungal susceptibility testing results of New Zealand yeast isolates, 2001-2015: Impact of recent CLSI breakpoints and epidemiological cut-off values for Candida and other yeast species.
Topics: Amphotericin B; Antifungal Agents; Candida; Caspofungin; Drug Resistance, Fungal; Fluconazole; Humans; Microbial Sensitivity Tests; Mycoses; New Zealand; Pichia | 2018 |
The patterns of colonization and antifungal susceptibility of Candida, isolated from preterm neonates in Khorramabad, South West of Iran.
Topics: Amphotericin B; Antifungal Agents; Candida; Candida albicans; Candida glabrata; Candidiasis, Invasive; Caspofungin; Drug Resistance, Fungal; Female; Fluconazole; Hospitals; Humans; Infant, Newborn; Infant, Premature; Iran; Itraconazole; Male; Microbial Sensitivity Tests; Voriconazole | 2018 |
A proposal for antifungal epidemiological cut-off values against Histoplasma capsulatum var. capsulatum based on the susceptibility of isolates from HIV-infected patients with disseminated histoplasmosis in Northeast Brazil.
Topics: Amphotericin B; Antifungal Agents; Brazil; Caspofungin; Echinocandins; Fluconazole; Histoplasma; Histoplasmosis; HIV; HIV Infections; Humans; Itraconazole; Lipopeptides; Microbial Sensitivity Tests; Retrospective Studies; Voriconazole | 2018 |
Genetic diversity and antifungal susceptibility of Candida albicans isolated from Iranian patients.
Topics: Antifungal Agents; Candida albicans; Candidiasis; Caspofungin; Cluster Analysis; Drug Resistance, Fungal; Fluconazole; Genetic Variation; Genotype; Humans; Iran; Itraconazole; Microbial Sensitivity Tests; Microbial Viability; Microsatellite Repeats | 2019 |
Comparison of the incidence, clinical features and outcomes of invasive candidiasis in children and neonates.
Topics: Adolescent; Amphotericin B; Antifungal Agents; Candida albicans; Candidiasis, Invasive; Caspofungin; Child; Child, Preschool; Cohort Studies; Female; Fluconazole; Fungemia; Hospital Mortality; Humans; Incidence; Infant; Infant, Newborn; Male; Risk Factors; Taiwan; Treatment Outcome | 2018 |
The first isolate of Candida auris in China: clinical and biological aspects.
Topics: Aged; Amphotericin B; Animals; Antifungal Agents; Bronchoalveolar Lavage Fluid; Candida; Candidemia; Caspofungin; China; Copper Sulfate; Echinocandins; Female; Fluconazole; Humans; Lipopeptides; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moths | 2018 |
Vulvovaginal candidiasis: species distribution of Candida and their antifungal susceptibility pattern.
Topics: Adolescent; Adult; Antifungal Agents; Candida albicans; Candidiasis, Vulvovaginal; Caspofungin; Cross-Sectional Studies; Drug Resistance, Fungal; Ethiopia; Female; Fluconazole; Flucytosine; Humans; Micafungin; Microbial Sensitivity Tests; Middle Aged; Prevalence; Reproductive Tract Infections; Sexual Partners; Voriconazole; Young Adult | 2018 |
A case report of purulent pericarditis caused by Candida albicans: Delayed complication forty-years after esophageal surgery.
Topics: Adult; Antifungal Agents; Candida albicans; Caspofungin; Colon; Drainage; Echinocandins; Esophageal Atresia; Female; Fluconazole; Humans; Lipopeptides; Long Term Adverse Effects; Mycoses; Pericarditis; Plastic Surgery Procedures; Suppuration; Treatment Outcome | 2018 |
Iranian HIV/AIDS patients with oropharyngeal candidiasis: identification, prevalence and antifungal susceptibility of Candida species.
Topics: Adolescent; Adult; Aged; Amphotericin B; Antifungal Agents; Candida albicans; Candidiasis, Oral; Caspofungin; Drug Resistance, Multiple, Fungal; Echinocandins; Female; Fluconazole; HIV Infections; Humans; Incidence; Iran; Itraconazole; Lipopeptides; Male; Microbial Sensitivity Tests; Middle Aged; Mouth; Prevalence; Young Adult | 2018 |
Polymorphism of Polymeric Amino Acid Regions in Fungal Proteins and Correlation with Altered Echinocandin and Azole Susceptibility.
Topics: Antifungal Agents; Azoles; Candida glabrata; Candidiasis; Caspofungin; Drug Resistance, Fungal; Echinocandins; Fluconazole; Fungal Proteins; Humans; Microbial Sensitivity Tests; Phylogeny; Polymorphism, Genetic | 2018 |
Impact of Antifungal Compounds on Viability and Anti-
Topics: Amphotericin B; Antifungal Agents; Caspofungin; Cell Survival; Deoxycholic Acid; Doxorubicin; Drug Combinations; Fluconazole; Humans; Killer Cells, Natural; Microbial Sensitivity Tests; Polyethylene Glycols; Triazoles; Voriconazole | 2019 |
Clinical Significance of the Floral Shift in Candidiasis.
Topics: Amphotericin B; Antifungal Agents; Azoles; Candida; Candida albicans; Candidiasis; Caspofungin; Drug Resistance, Fungal; Fluconazole; Humans; Nystatin; Oils, Volatile; Voriconazole | 2018 |
Species distribution and antifungal drug susceptibilities of yeasts isolated from the blood samples of patients with candidemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amphotericin B; Anidulafungin; Antifungal Agents; Candida; Candida albicans; Candida glabrata; Candida parapsilosis; Candidemia; Caspofungin; Child; Child, Preschool; Female; Fluconazole; Flucytosine; Humans; Itraconazole; Male; Micafungin; Microbial Sensitivity Tests; Middle Aged; Triazoles; Voriconazole; Young Adult | 2019 |
Nitroglycerin-Citrate-Ethanol Catheter Lock Solution Is Highly Effective for
Topics: Amphotericin B; Anidulafungin; Antifungal Agents; Biofilms; Candida; Caspofungin; Catheter-Related Infections; Catheters; Citric Acid; Ethanol; Fluconazole; Micafungin; Nitroglycerin; Pharmaceutical Solutions; Voriconazole | 2019 |
Successful treatment of a
Topics: Aged; Amphotericin B; Antifungal Agents; Candida; Candidiasis; Cartilage, Articular; Caspofungin; Drug Therapy, Combination; Female; Fluconazole; Humans | 2019 |
Evaluation of Candida colonization and use of the Candida Colonization Index in a paediatric Intensive Care Unit: a prospective observational study.
Topics: Adolescent; Amphotericin B; Antifungal Agents; Candida; Candidemia; Caspofungin; Child; Child, Preschool; Disease Susceptibility; Feasibility Studies; Female; Fluconazole; Humans; Infant; Intensive Care Units, Pediatric; Itraconazole; Male; Microbial Sensitivity Tests; Organ Specificity; Prospective Studies; Sensitivity and Specificity; Voriconazole | 2019 |
Necessity to identify candida species accurately with minimum inhibitory concentration determination in each case of bloodstream infections.
Topics: Amphotericin B; Antifungal Agents; Bacteremia; Candida; Candida tropicalis; Candidiasis; Caspofungin; Cross-Sectional Studies; Fluconazole; Humans; Intensive Care Units; Microbial Sensitivity Tests; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Voriconazole | 2020 |
Evaluation of first-line therapies for the treatment of candidemia in ICU patients: A propensity score analysis.
Topics: Aged; Antifungal Agents; Candidemia; Caspofungin; Cohort Studies; Critical Illness; Female; Fluconazole; Humans; Intensive Care Units; Kaplan-Meier Estimate; Male; Middle Aged; Propensity Score; Retrospective Studies; Treatment Outcome; Voriconazole | 2020 |
Prophylaxis Against Invasive Fungal Disease for Neutropenic Children and Young Adults.
Topics: Antifungal Agents; Caspofungin; Child; Fluconazole; Humans; Leukemia, Myeloid, Acute; Mycoses; Young Adult | 2020 |
Quantification of 1,3-β-d-glucan by Wako β-glucan assay for rapid exclusion of invasive fungal infections in critical patients: A diagnostic test accuracy study.
Topics: Aged; Antifungal Agents; beta-Glucans; Caspofungin; Diagnostic Tests, Routine; Female; Fluconazole; Humans; Intensive Care Units; Invasive Fungal Infections; Limit of Detection; Male; Middle Aged; Predictive Value of Tests; Retrospective Studies; Sensitivity and Specificity; Voriconazole | 2020 |
Impact of biofilm production by Candida species and antifungal therapy on mortality of patients with candidemia.
Topics: Adult; Aged; Aged, 80 and over; Biofilms; Candida; Candidemia; Caspofungin; Echinocandins; Female; Fluconazole; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Multivariate Analysis; Taiwan; Tertiary Care Centers | 2020 |
Molecular identification, biofilm formation and antifungal susceptibility of Rhodotorula spp.
Topics: Amphotericin B; Antifungal Agents; Biofilms; Caspofungin; DNA, Fungal; DNA, Ribosomal Spacer; Fluconazole; Humans; Imidazoles; Itraconazole; Microbial Sensitivity Tests; Phylogeny; Rhodotorula; Species Specificity; Triazoles; Voriconazole | 2020 |
Fungal endocarditis with heart valve replacement and atrial fibrillation posing a treatment challenge: A case report.
Topics: Antifungal Agents; Atrial Fibrillation; Candida parapsilosis; Candidiasis; Caspofungin; Combined Modality Therapy; Diagnosis, Differential; Endocarditis, Non-Infective; Female; Fluconazole; Hemiplegia; Humans; Infarction, Middle Cerebral Artery; Middle Aged; Mitral Valve; Prosthesis-Related Infections; Warfarin | 2020 |
Effect of antifungal agents, lysozyme and human antimicrobial peptide LL-37 on clinical
Topics: Amphotericin B; Antifungal Agents; Antimicrobial Cationic Peptides; Biofilms; Candida parapsilosis; Candida tropicalis; Caspofungin; Cathelicidins; Drug Combinations; Fluconazole; Humans; Muramidase | 2021 |
Categorizing Susceptibility of Clinical Isolates of
Topics: Amphotericin B; Antifungal Agents; Candida; Caspofungin; Fluconazole; Humans; Microbial Sensitivity Tests | 2021 |
Impact of antifungal stewardship interventions on the susceptibility of colonized Candida species in pediatric patients with malignancy.
Topics: Adolescent; Amphotericin B; Antifungal Agents; Antimicrobial Stewardship; Candida; Caspofungin; Child; Child, Preschool; Colony Count, Microbial; Disease Susceptibility; Drug Resistance, Fungal; Female; Fluconazole; Humans; Male; Microbial Sensitivity Tests; Neoplasms; Triazoles | 2021 |
Antifungal susceptibility profile of invasive
Topics: Amphotericin B; Anidulafungin; Antifungal Agents; Candida glabrata; Candidemia; Caspofungin; Cross-Sectional Studies; Drug Resistance, Fungal; Fluconazole; Humans; Micafungin; Pakistan; Retrospective Studies; Tertiary Care Centers | 2021 |
Successful fluconazole combined with caspofungin treatment of candida bloodstream infection in preterm infant: A case report.
Topics: Amphotericin B; Antifungal Agents; Candida parapsilosis; Candidemia; Caspofungin; Female; Fluconazole; Humans; Infant, Newborn; Infant, Premature; Male; Microbial Sensitivity Tests; Treatment Outcome | 2021 |
Comparison of Six Antifungal Susceptibilities of 11
Topics: Amphotericin B; Antifungal Agents; Candida; Candida albicans; Caspofungin; Drug Resistance, Fungal; Fluconazole; Micafungin; Microbial Sensitivity Tests; Voriconazole | 2022 |
Clinical impact of Candida respiratory tract colonization and acute lung infections in critically ill patients with COVID-19 pneumonia.
Topics: Amphotericin B; Antifungal Agents; Candida; Candida albicans; Candida glabrata; Candidiasis; Caspofungin; COVID-19; Critical Illness; Fluconazole; Humans; Lung; Microbial Sensitivity Tests; Pneumonia; SARS-CoV-2 | 2022 |
In vitro synergistic antifungal activities of caspofungin in combination with fluconazole or voriconazole against Candida species determined by the Etest method.
Topics: Antifungal Agents; Candida; Candida glabrata; Caspofungin; Disk Diffusion Antimicrobial Tests; Drug Resistance, Fungal; Fluconazole; Humans; Microbial Sensitivity Tests; Triazoles; Voriconazole | 2022 |
Comparison of simulated candidemia detection during prophylactic antifungal therapy.
Topics: Antifungal Agents; Candida; Candida albicans; Candida glabrata; Candida parapsilosis; Candida tropicalis; Candidemia; Caspofungin; Fluconazole; Humans; Micafungin; Microbial Sensitivity Tests | 2022 |
Cost-utility analysis of caspofungin and fluconazole for primary treatment of invasive candidiasis and candidemia in Ethiopia.
Topics: Adult; Antifungal Agents; Candidemia; Candidiasis, Invasive; Caspofungin; Cost-Benefit Analysis; Echinocandins; Ethiopia; Fluconazole; Humans; Lipopeptides | 2022 |
In Vitro Antifungal Activity of Azoles and Other Antifungal Agents Against Pathogenic Yeasts from Vulvovaginal Candidiasis in China.
Topics: Antifungal Agents; Azoles; Candida; Candida albicans; Candida glabrata; Candidiasis, Vulvovaginal; Caspofungin; Female; Fluconazole; Humans; Itraconazole; Voriconazole | 2023 |
The In Vitro Activity of Fluconazole, Amphotericin B and Echinocandins Against Cyberlindnera fabianii Planktonic Cells and Biofilms.
Topics: Amphotericin B; Anidulafungin; Biofilms; Caspofungin; Echinocandins; Fluconazole; Micafungin | 2023 |
Antifungal activity and potential mechanism of action of caspofungin in combination with ribavirin against Candida albicans.
Topics: Antifungal Agents; Biofilms; Candida albicans; Caspofungin; Echinocandins; Fluconazole; Humans; Microbial Sensitivity Tests; Ribavirin | 2023 |
Comparison of in vitro activities of newer triazoles and classic antifungal agents against dermatophyte species isolated from Iranian University Hospitals: a multi-central study.
Topics: Antifungal Agents; Arthrodermataceae; Caspofungin; Fluconazole; Griseofulvin; Hospitals, University; Humans; Iran; Itraconazole; Terbinafine; Triazoles | 2023 |
Aspects related to biofilm production and antifungal susceptibility of clinically relevant yeasts of the genus Trichosporon.
Topics: Amphotericin B; Animals; Antifungal Agents; Biofilms; Caspofungin; Fluconazole; Humans; Itraconazole; Microbial Sensitivity Tests; Trichosporon; Trichosporonosis | 2023 |
Phenotypic and genotypic characterization of virulence markers and antifungal susceptibility of oral Candida species from diabetic and non-diabetic hemodialysis patients.
Topics: Amphotericin B; Antifungal Agents; Candida; Candida albicans; Candida glabrata; Caspofungin; Drug Resistance, Fungal; Fluconazole; Humans; Itraconazole; Microbial Sensitivity Tests; Peptide Hydrolases; Phospholipases; Virulence; Voriconazole | 2023 |
Azole non-susceptible C. tropicalis and polyclonal spread of C. albicans in Central Vietnam hospitals.
Topics: Antifungal Agents; Azoles; Candida; Candida albicans; Caspofungin; Fluconazole; Hospitals; Multilocus Sequence Typing; Vietnam | 2023 |
Rapid automated antifungal susceptibility testing system for yeasts based on growth characteristics.
Topics: Anidulafungin; Antifungal Agents; Candida; Caspofungin; Fluconazole; Micafungin; Microbial Sensitivity Tests; Reproducibility of Results; Voriconazole; Yeasts | 2023 |
In vitro combination of antifungal drugs with tacrolimus (FK506) holds promise against clinical Candida species, including Candida auris.
Topics: Anidulafungin; Animals; Antifungal Agents; Candida; Candida auris; Candida glabrata; Candida parapsilosis; Caspofungin; Echinocandins; Fluconazole; Itraconazole; Microbial Sensitivity Tests; Tacrolimus | 2023 |